[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 348
1. Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ, Hu PJ: Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment Pharmacol Ther; 2006 Jan 15;23(2):289-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese.
  • BACKGROUND: Peroxisome proliferator-activated receptor gamma inhibits the growth and induces apoptosis of gastric cancer cells.
  • AIM: To study the association between peroxisome proliferator-activated receptor gamma gene polymorphism, Helicobacter pylori infection and gastric cancer in Chinese.
  • METHODS: One hundred and four consecutive patients with non-cardia gastric adenocarcinoma and 104 matched controls were examined.
  • While H. pylori infection was more prevalent in gastric cancer patients (OR 3.0; 95% CI 1.6-5.7), the combination of peroxisome proliferator-activated receptor gamma G allele and H. pylori infection further increased the risk of gastric cancer (OR 12.8, 95% CI 3.2-50.5).
  • The presence of the Ala12 did not increase the risk of gastric cancer in H. pylori-negative subjects.
  • CONCLUSION: Our study suggests the potential association between peroxisome proliferator-activated receptor gamma polymorphism and H. pylori infection in the development of non-cardia gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Helicobacter pylori. PPAR gamma / genetics. Polymorphism, Restriction Fragment Length. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393309.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PPAR gamma
  •  go-up   go-down


2. Shiraishi T, Shimizu I, Horie T, Okazaki M, Teraoka M, Takeichi K, Uehara K, Fujiwara K, Fujiwara S, Yamamoto H, Iuchi A, Wakatsuki S, Ito S: A patient with octopus pot-shaped cardial cancer that metastasized to multiple organs. J Med Invest; 2005 Feb;52(1-2):122-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autopsy revealed a protruding lesion measuring about 3 cm with erosion measuring 5 mm in diameter immediately below the esophago-gastric conjugation site, suggesting primary cardial undifferentiated adenocarcinoma.
  • In the primary focus, changes on the mucosal surface were almost normal However, below the mucosa, infiltration of cancer cells was observed in an approximately 3 cm area along the gastric wall.
  • In our patient, metastatic lesions were detected in multiple organs, including the stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Gastric Mucosa / pathology. Humans. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751284.001).
  • [ISSN] 1343-1420
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Wang DC, Wang LD, Zheng S, Fan ZM, Li JL, Feng CW, Zhang YR, Liu B, Gao SS, He X: [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The application of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma].
  • OBJECTIVES: To evaluate the serum biomarkers for diagnosis of gastric cardia dysplasia (DYS) and chronic atrophic gastric-carditis (CAG) and to provide a novel screening method for high risk population of gastric-cardia adenocarcinoma (GCA).
  • A set of spectra derived from analysis of serum from 143 symptom-free subjects at high-risk area for GCA, including 63 cases with histologically normal gastric cardia epithelia, 57 of CAG and 23 of DYS, were analyzed by bioinformatics like decision tree classification algorithm.
  • CONCLUSIONS: The gastric cardia lesions of DYS and CAG could be identified by SELDI-TOF-MS technique specifically in symptom-free subjects at high incidence area for GCA.
  • [MeSH-major] Biomarkers, Tumor / blood. Cardia. Gastritis, Atrophic / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194406.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. McGrath K, Brody D, Luketich J, Khalid A: Detection of unsuspected left hepatic lobe metastases during EUS staging of cancer of the esophagus and cardia. Am J Gastroenterol; 2006 Aug;101(8):1742-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of unsuspected left hepatic lobe metastases during EUS staging of cancer of the esophagus and cardia.
  • The frequency at which occult liver metastases are detected during EUS staging of cancer of the esophagus and cardia is unknown.
  • METHODS: Over an 18-month period, 98 patients underwent EUS staging for a new diagnosis of cancer of the esophagus and cardia.
  • CONCLUSION: Curvilinear EUS examination of the left hepatic lobe in addition to standard radial EUS examination can be performed safely when staging cancer of the esophagus and cardia.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Cardia / pathology. Endosonography. Esophageal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790035.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Buckland G, Agudo A, Luján L, Jakszyn P, Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V, Sacerdote C, Tumino R, Panico S, Nesi G, Manjer J, Regnér S, Johansson I, Stenling R, Sanchez MJ, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen NE, Key TJ, Bingham S, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Morois S, Boutron-Ruault MC, Trichopoulou A, Lagiou P, Trichopoulos D, Lund E, Couto E, Boffeta P, Jenab M, Riboli E, Romaguera D, Mouw T, González CA: Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr; 2010 Feb;91(2):381-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study.
  • OBJECTIVE: We aimed to explore the association between adherence to a relative Mediterranean diet (rMED) and incident gastric adenocarcinoma (GC) within the European Prospective Investigation into Cancer and Nutrition study.
  • The association between rMED and GC with respect to anatomic location (cardia and noncardia) and histologic types (diffuse and intestinal) was investigated.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007304.001).
  • [ISSN] 1938-3207
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] ENG
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / 11692; United Kingdom / Medical Research Council / / ; United Kingdom / Department of Health / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Bastos J, Lunet N, Peleteiro B, Lopes C, Barros H: Dietary patterns and gastric cancer in a Portuguese urban population. Int J Cancer; 2010 Jul 15;127(2):433-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and gastric cancer in a Portuguese urban population.
  • We aimed to quantify the association between dietary patterns and gastric cancer, by location and histological type, according to Helicobacter pylori infection status.
  • We analyzed 591 incident cases of gastric adenocarcinoma and 1,463 community controls.
  • Compared to pattern I, the risk of gastric cancer was higher for pattern II (OR = 1.68, 95% CI: 1.31-2.14) but not for pattern III (OR = 0.80, 95% CI: 0.57-1.14), with no effect modification by H. pylori infection.
  • The association was similar for cardia and non-cardia gastric cancer, but for tumors of the diffuse Laurén histological type, the association was weaker for pattern II vs. I (OR = 1.32, 95% CI: 0.83-2.08) and a protective effect was observed for pattern III vs. I (OR = 0.43, 95% CI: 0.22-0.87).
  • [MeSH-major] Adenocarcinoma / epidemiology. Diet. Stomach Neoplasms / epidemiology. Urban Population / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia. Case-Control Studies. Female. Helicobacter Infections / complications. Helicobacter Infections / microbiology. Helicobacter pylori / isolation & purification. Humans. Male. Middle Aged. Nutrition Surveys. Portugal / epidemiology. Prognosis. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876925.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH: Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control; 2009 Apr;20(3):361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.
  • A number of risk factors for esophageal and gastric cancers have emerged, yet little is known whether risk factors map to molecular tumor markers such as overexpression of the tumor suppressor TP53.
  • Using a US multicenter, population-based case-control study (170 cases of esophageal adenocarcinomas, 147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, and 112 esophageal squamous cell carcinomas), we examined whether the risk associated with cigarette smoking, body mass index (BMI), gastroesophageal reflux disease (GERD), and non-steroidal anti-inflammatory drug (NSAID) use varied by P53 overexpression.
  • The proportion of cases overexpressing P53 by tumor subtype was 72% for esophageal adenocarcinoma, 69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67% for esophageal squamous cell carcinoma.
  • For non-cardia gastric cancer however, an association with cigarette smoking was suggested for tumors that do not overexpress P53, whereas larger BMI was related to adenocarcinomas that overexpress P53 versus no overexpression.
  • Overall, this study did not find a clear relationship between P53 protein overexpression and the known risk factors for subtypes of esophageal and gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Vojnosanit Pregl. 2005 Dec;62(12):879-85 [16375215.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2914-8 [8187077.001]
  • [Cites] Carcinogenesis. 1995 May;16(5):993-1002 [7767998.001]
  • [Cites] Pathol Res Pract. 1994 Dec;190(12):1141-8 [7540752.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):425-32 [9028350.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Mod Pathol. 2001 May;14(5):397-403 [11353048.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):233-40 [11902578.001]
  • [Cites] Oncology. 2002;62(2):175-9 [11914604.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1729-35 [14583777.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):779-82 [9332759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1065-9 [9419404.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Cancer. 1998;77(2):277-86 [9460999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):591-7 [10223186.001]
  • [Cites] J Pathol. 1999 Jan;187(1):8-18 [10341702.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):63-8 [15621992.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):225-30 [15765441.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • (PMID = 18989634.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] None / None / / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; None / None / / U01 CA057983-03; United States / Intramural NIH HHS / / Z01 CP010136-12; United States / NCI NIH HHS / CA / U01 CA057923; United States / NCI NIH HHS / CA / U01 CA 57923; United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NCI NIH HHS / CA / U01 CA 57983; United States / NCI NIH HHS / CA / U01 CA 57049; None / None / / U01 CA057949-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS100106; NLM/ PMC2726999
  •  go-up   go-down


8. Hampel H, Abraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med; 2005 Aug 2;143(3):199-211
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of body mass index and gastroesophageal reflux disease (GERD), including its complications (esophagitis, Barrett esophagus, and esophageal adenocarcinoma), is unclear.
  • PURPOSE: To conduct a systematic review and meta-analysis to estimate the magnitude and determinants of an association between obesity and GERD symptoms, erosive esophagitis, Barrett esophagus, and adenocarcinoma of the esophagus and of the gastric cardia.
  • Six of 7 studies found significant associations of BMI with erosive esophagitis, 6 of 7 found significant associations with esophageal adenocarcinoma, and 4 of 6 found significant associations with gastric cardia adenocarcinoma.
  • Similarly, the pooled adjusted odds ratios for esophageal adenocarcinoma for BMI of 25 kg/m2 to 30 kg/m2 and BMI greater than 30 kg/m2 were 1.52 (CI, 1.147 to 2.009) and 2.78 (CI, 1.850 to 4.164), respectively.
  • CONCLUSION: Obesity is associated with a statistically significant increase in the risk for GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Esophagitis / etiology. Humans. Odds Ratio. Risk Factors


9. Liu W, Hao XS, Fan Q, Li HX, Song LN, Wang SJ, Wang PZ, Jin Y, Chen Y, Guan LY, Ping YM, Meng XL, Wang R, Liu JF, Wang XL: [Cox proportional hazard model analysis of prognosis in patients with carcinoma of esophagus and gastric cardia after radical resection]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):921-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cox proportional hazard model analysis of prognosis in patients with carcinoma of esophagus and gastric cardia after radical resection].
  • OBJECTIVE: To investigate the factors affecting the long-term survival of patients with carcinoma of esophagus and gastric cardia after curative resection.
  • METHODS: The clinical data of 906 patients with carcinoma of esophagus and gastric cardia treated by radical resection in 1996 - 2004 were analyzed retrospectively.
  • CONCLUSION: The independent prognostic factors of the patients with carcinoma of esophagus and gastric cardia are pathologic differentiation, TNM stage, number of metastatic lymph nodes, and involvement of adjacent organs.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Cardia. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophagectomy / methods. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173994.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


10. Isgüder AS, Nazli O, Tansug T, Bozdag AD, Onal MA: Total gastrectomy for gastric carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for gastric carcinoma.
  • BACKGROUND/AIMS: Gastric cancer is one of the most common organ cancers all around the world and surgical resection is essential for treatment.
  • Total gastrectomy is the procedure of choice for treatment of proximal gastric cancer.
  • METHODOLOGY: Thirty-eight gastric cancer patients underwent total gastrectomy in the Third Surgical Clinic of Izmir Ataturk Training and Research Hospital between 1996 and 2001.
  • Sites of the tumors were: cardia 28.9%, cardia and corpus 15.8%, corpus 34.3%, corpus and antrum 18.4%, linitis plastica 2.6%.
  • Histological types were adenocarcinoma (97.4%), and squamous cell carcinoma (2.6%).
  • Gastric tubes were removed on the fourth postoperative day.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU: Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer; 2006 Aug 1;119(3):702-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period.
  • The prediction of Helicobacter pylori antibodies immunoglobulin A (IgA) and immunoglobulin G (IgG) and serum pepsinogen I (PG I) on gastric cancer occurrence was studied in a nested case-control study, based on 225 incident cancer cases and 435 matched controls from a Finnish cohort followed from 1966-1991.
  • The odds ratio of noncardia gastric cancer between infected and noninfected persons was 3.12 (95% confidence interval (CI)=1.97-4.95) for elevated IgA and 2.88 (CI: 1.63-5.07) for elevated IgG antibodies.
  • IgA antibodies were significantly associated with all registered histological subtypes apart from intestinal type adenocarcinoma.
  • The highest gastric cancer risk was found among individuals with simultaneously elevated IgA and IgG antibodies and low PG I with an odds ratio of 10.9 (CI: 4.31-27.7) in comparison with those who were negative for both antibodies and had normal PG I.
  • Elevated IgA and IgG antibodies and low PG I were not associated with cancers of the gastric cardia.
  • The findings support the hypothesis that H. pylori infection is a cause of noncardia gastric cancer.
  • Although elevated H. pylori IgA and IgG antibodies and low PG I independently could predict the occurrence of noncardia gastric cancer, their power to do so varied with the stage and length of the follow-up period and it increased when they were applied in combination.
  • [MeSH-major] Antibodies, Bacterial / blood. Helicobacter Infections / complications. Helicobacter pylori / immunology. Pepsinogen A / blood. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16496404.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 9001-10-9 / Pepsinogen A
  •  go-up   go-down


12. Bor S, Vardar R, Ormeci N, Memik F, Suleymanlar I, Oguz D, Colakoglu S, Yucesoy M, Turkdogan K, Gurel S, Dogan I, Yildirim B, Goral V, Dokmeci G, Okcu N, Duman D, Simsek I, Demir A: Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol; 2007 Dec;22(12):2242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori.
  • AIM: In developed countries, there has been a recent increase in the prevalence of adenocarcinoma of the esophagus and cardia, along with a decrease in distal gastric cancers.
  • The aim of the present study was to evaluate changes in the prevalence of gastric adenocarcinomas in Turkey as a function of anatomic location.
  • Owing to the exclusion criteria, a total of 4065 cases of tumors of the stomach and distal esophagus were included.
  • The ratio of distal/proximal adenocarcinoma was 2,1 [corrected] for the western part of Turkey and 3,8 [corrected] for the eastern part of the country (P < 0.0001), and this did not change during the 11 years. H. pylori was detected significantly less in the west compared to the east for distal tumors (65.7 vs 38.7%, respectively, P = 0.02).
  • CONCLUSION: In Turkey, a developing country with a high H. pylori prevalence, contrary to the state of developed countries, the ratio of distal versus proximal gastric adenocarcinomas has not changed.
  • Geographical distribution should be taken into the account in projecting the changing patterns of gastric cancers.
  • [MeSH-major] Developing Countries. Helicobacter pylori. Stomach Neoplasms / epidemiology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1309
  • (PMID = 18031388.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE: Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut; 2009 Jan;58(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females.
  • BACKGROUND AND AIMS: Upper gastrointestinal adenocarcinomas show an unexplained male predominance that is more apparent in oesophagus than stomach and in intestinal than diffuse histological subtype.
  • METHOD AND MATERIALS: Of 3270 gastric and oesophageal cancers recorded in the West of Scotland Cancer Registry, 1998-2002, 812 were randomly selected for detailed analysis.
  • The Lauren histological subtype of adenocarcinoma was determined by reviewing 1204 original reports and 3241 biopsies.
  • RESULTS: Analysis included 405 non-cardia cancers, 173 cardia cancers and 209 oesophageal adenocarcinomas.
  • The M/F ratios for oesophageal, cardia and non-cardia gastric cancer were 3.5, 2.0 and 1.6, respectively.
  • CONCLUSION: Male predominance of upper gastrointestinal adenocarcinoma is related to the intestinal histological subtype rather than tumour location and is due to marked delayed development of this subtype in females prior to 50-60 years of age.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology


14. Trouillet N, Robert B, Charfi S, Bartoli E, Joly JP, Chatelain D: Gastric metastases. An endoscopic series of ten cases. Gastroenterol Clin Biol; 2010 Apr-May;34(4-5):305-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric metastases. An endoscopic series of ten cases.
  • We report a series of ten cases of the clinical, endoscopic and pathological features of gastric metastases.
  • Patients were six women and four men between 54 and 88 years old, with gastric metastases from breast carcinoma (4), lung carcinoma (4) and melanoma (2).
  • Metastases were located in the cardia (2), fundus (5) and antrum (3).
  • The microscopic features of the gastric metastases resembled a primary gastric cancer in eight cases.
  • Thanks to clinical data, the pathologist confirmed the diagnosis of gastric metastases on immunohistochemistry.
  • Gastric metastases are rare, occur at a late stage of the neoplastic disease, and have a poor prognosis.
  • Diagnosis of gastric metastases is difficult because they simulate primary gastric cancer on endoscopy and on microscopic examination.
  • [MeSH-major] Endoscopy, Gastrointestinal. Stomach Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627637.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Guo W, Cui YJ, Fang SM, Li Y, Wang N, Zhang JH: [Association of polymorphisms of p21cip1 and p27kip1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. Ai Zheng; 2006 Feb;25(2):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of polymorphisms of p21cip1 and p27kip1 genes with susceptibilities of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
  • This study was to investigate the possible association of functional polymorphisms of p21(cip1) and p27(kip1) genes with susceptibilities of esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in a population from a high incidence region in north China.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Esophageal Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Cardia. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Smoking

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480585.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


16. Lu CC, De-Chuan C, Lee HS, Chu HC: Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases. Am J Surg; 2010 Apr;199(4):e42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases.
  • The authors report a rare case of hepatoid adenocarcinoma of the stomach, presenting initially with spleen and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cardia. Liver Neoplasms / diagnosis. Lymph Nodes / pathology. Splenic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359564.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


17. Sadighi S, Raafat J, Mohagheghi M, Meemary F: Gastric carcinoma: 5 year experience of a single institute. Asian Pac J Cancer Prev; 2005 Apr-Jun;6(2):195-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric carcinoma: 5 year experience of a single institute.
  • PURPOSE: Gastric cancer (GC) is the most common cause of cancer death registered in cancer institute.
  • Most common site of involvement was cardia (43%).
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101332.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


18. Chandrasoma P: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2005 Apr;46(4):361-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent data indicate that the only normal epithelia in the oesophagus and proximal stomach are squamous epithelium and gastric oxyntic mucosa.
  • When this fact is recognized, it becomes easy to develop precise histological definitions for the normal state (presence of only squamous and oxyntic mucosa), metaplastic oesophageal columnar epithelium (cardiac mucosa with and without intestinal metaplasia, and oxynto-cardiac mucosa), the gastro-oesophageal junction (the proximal limit of gastric oxyntic mucosa), the oesophagus (that part of the foregut lined by squamous and metaplastic columnar epithelium), reflux disease (the presence of metaplastic columnar epithelium), and Barrett's oesophagus (cardiac mucosa with intestinal metaplasia).
  • It is also possible to assess accurately the severity of reflux which is directly proportional to the amount of metaplastic columnar epithelium, and the risk of adenocarcinoma which is related to the amount of dysplasia in intestinal metaplastic epithelium present within the columnar lined segment of the oesophagus.
  • [MeSH-major] Barrett Esophagus / pathology. Cardia / pathology. Gastric Mucosa / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):97-8; author reply 98 [16842257.001]
  • (PMID = 15810947.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


19. Mottershead M, Karteris E, Barclay JY, Suortamo S, Newbold M, Randeva H, Nwokolo CU: Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma. J Clin Pathol; 2007 Apr;60(4):405-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma.
  • BACKGROUND: Ghrelin is an orexigenic gut peptide produced predominantly by the stomach.
  • Gastric mucosal ghrelin production could be compromised by an infiltrating adenocarcinoma.
  • METHODS: 10 gastric and 22 oesophageal adenocarcinoma archival samples were randomly selected from a database.
  • Quantitative reverse transcriptase polymerase chain reaction (PCR) for ghrelin mRNA was also performed on 24 gastric and 8 oesophageal adenocarcinoma specimens and adjacent non-neoplastic mucosa.
  • RESULTS: Immunohistochemistry and reverse transcriptase PCR confirm a negligible expression of ghrelin in adenocarcinoma specimens.
  • By contrast, non-neoplastic gastric mucosa was rich in ghrelin-positive cells and ghrelin mRNA.
  • The number (median and range) of ghrelin-positive cells per 2 mm section of non-neoplastic mucosa was 73 (45-215) in the corpus; this was significantly higher than in cardia mucosa (9 (0-64), p<0.001) and antral mucosa (5 (0-14), p<0.001).
  • CONCLUSIONS: Gastric and oesophageal adenocarcinomas have no ghrelin-producing cells.
  • The highest level of ghrelin expression was noted in the non-neoplastic mucosa of the gastric corpus.
  • Disruption of the gastric ghrelin-producing mechanism may occur during oesophagogastric malignancy.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Peptide Hormones / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Gastric Mucosa / metabolism. Ghrelin. Humans. Immunoenzyme Techniques. Neurosecretory Systems / metabolism. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Dec 9;402(6762):656-60 [10604470.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1623-30 [12023994.001]
  • [Cites] Nature. 2000 Oct 19;407(6806):908-13 [11057670.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):4255-61 [11089560.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4908-11 [11134161.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):194-8 [11196643.001]
  • [Cites] Eur J Endocrinol. 2000 Dec;143(6):R11-4 [11124868.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):788-94 [11159851.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):881-7 [11158061.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1464-9 [11297568.001]
  • [Cites] Trends Endocrinol Metab. 2001 Apr;12(3):118-22 [11306336.001]
  • [Cites] J Endocrinol Invest. 2001 Jun;24(6):RC19-21 [11434675.001]
  • [Cites] Diabetes. 2001 Aug;50(8):1714-9 [11473029.001]
  • [Cites] Gut. 2002 Jun;50 Suppl 5:v1-23 [12049068.001]
  • [Cites] Histochem Cell Biol. 2002 Jun;117(6):511-9 [12107501.001]
  • [Cites] Histochem Cell Biol. 2002 Jun;117(6):521-5 [12107502.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1120-8 [12360474.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):774-8 [12576449.001]
  • [Cites] Diabetes. 2003 Apr;52(4):948-56 [12663466.001]
  • [Cites] Gut. 2003 Jul;52(7):947-52 [12801949.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):143-61 [12831935.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3117-20 [12843152.001]
  • [Cites] Gut. 2003 Oct;52(10):1391-2 [12970126.001]
  • [Cites] FEBS Lett. 2003 Sep 25;552(2-3):105-9 [14527669.001]
  • [Cites] Gut. 2004 Feb;53(2):187-94 [14724148.001]
  • [Cites] Eur J Cancer. 1991;27(1):9-15 [1826450.001]
  • [Cites] Ann Surg. 1994 Apr;219(4):325-31 [7512810.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):277-87 [9208884.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1293-7 [9260792.001]
  • [Cites] Biotech Histochem. 2005 May-Aug;80(3-4):163-8 [16298902.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4753-8 [11600536.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):5052-9 [11600584.001]
  • [Cites] Diabetes. 2001 Nov;50(11):2540-7 [11679432.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5992 [11739476.001]
  • [Cites] Peptides. 2002 Mar;23(3):531-6 [11836003.001]
  • [Cites] J Endocrinol Invest. 2000 Sep;23(8):493-5 [11021763.001]
  • (PMID = 16751299.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2001112
  •  go-up   go-down


20. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR: Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol; 2008 May;3(5):516-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
  • PURPOSE: This study was undertaken to explore the response rate of a first-line, three-drug regimen that consisted of bortezomib, paclitaxel, and carboplatin in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2006 Aug;59(2):128-38 [16829119.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2546-8 [15958811.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88 [9427274.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):960-5 [15151955.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Nov;126(5):1603-8 [14666040.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15 [16763792.001]
  • [Cites] Anticancer Drugs. 2007 Jul;18(6):677-86 [17762396.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4647-51 [17671158.001]
  • (PMID = 18449005.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / U10 CA037417; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA035269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA-52654; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA063849; United States / NCI NIH HHS / CA / CA-35119; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / N01 CA015083; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS547678; NLM/ PMC3929582
  •  go-up   go-down


21. Jovanović I, Todorović V, Milosavljević T, Micev M, Pesko P, Bjelović M, Mouzas Y, Tzardi M: Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum. Vojnosanit Pregl; 2005 Dec;62(12):879-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum.
  • BACKGROUND/AIM: Most studies of esophageal and gastric adenocarcinomas have shown a very high rate of p53 gene mutation and/or protein overexpression, but the influence of the tumour site upon the frequency of p53 protein expression has not been evaluated (gastroesophageal junction, Barret's esophagus, and antrum).
  • METHODS: The material comprised 66 surgical specimens; 10 were Barrett's carcinomas, 25 adenocarcinomas of the gastric cardia (type II adenocarcinoma of the esophagogastric junction - EGJ), and 31 adenocarcinomas of the antrum.
  • There was, however, a significant difference observed in the depth of tumour invasion between Barrett's adenocarcinoma and adenocarcinoma of the cardia compared with the adenocarcinoma of the antrum.
  • Namely, at the time of surgery, both Barrett's adenocarcinomas and adenocarcinomas of the cardia, were significantly more advanced comparing with the adenocarcinomas of the antrum.
  • Overexpression of p53 was found in 40% (4/10) of Barrett's adenocarcinomas, 72% (18/25) of adenocarcinoma of the cardia and 65% (20/31) of adenocarcinoma of the antrum.
  • Patients with more advanced Barrett's adenocarcinoma and in the cases of lymph node invasion revealed tendency for the greater p53 positivity compared with the early forms and lymph node-negative cases; however, this difference was not significant according to the statistical analysis.
  • With regard to adenocarcinoma of the cardia, higher rates of p53 positivity were recorded in poorly differentiated, more advanced cases with lymph node invasion.
  • On the contrary, in the patients with adenocarcinoma of the antrum, greater p53 positivity was revealed in early forms without lymph node involvement, but the observed difference was not statistically significant.
  • CONCLUSION: No significant differences in p53 protein expression in terms of sex, type (Lauren) of tumour, depth of invasion, lymph node involvement, or tumour differentiation were observed in any of the analyzed groups of tumours (Barrett's adenocarcinoma, adenocarcinoma of the cardia and adenocarcinoma of the antrum).
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / complications. Cardia. Esophageal Neoplasms / metabolism. Pyloric Antrum. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Jan;63(1):87-8; author reply 88-9 [16471255.001]
  • (PMID = 16375215.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


22. Lindblad M, Ye W, Lindgren A, Lagergren J: Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg; 2006 Apr;243(4):479-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates.
  • OBJECTIVE: To evaluate the diagnostic accuracy of esophageal and cardia adenocarcinoma in the Swedish Cancer Register.
  • SUMMARY BACKGROUND DATA: Based on cancer registers, a rising incidence of esophageal and cardia adenocarcinoma has been reported in several populations, but possible influence of differences in tumor classification has not been evaluated.
  • METHODS: In a nationwide study in 1995 through 1997, all Swedish patients, born in Sweden and younger than 80 years with esophageal or cardia adenocarcinoma and half of all patients with esophageal squamous cell carcinoma, were prospectively, uniformly, and thoroughly classified.
  • RESULTS: The overall completeness of the Cancer Register was high (98.3%), whereas the site-specific completeness of the Register was 63% for esophageal adenocarcinoma, 74% for cardia adenocarcinoma, and 91% for esophageal squamous cell carcinoma.
  • The incidence of esophageal adenocarcinomas was 16% higher in the study classification compared with that of the Register during the study period, whereas the incidence of cardia adenocarcinoma was 2% lower in the study classification.
  • CONCLUSIONS: There is a diagnostic mismatch between esophageal and cardia adenocarcinoma in the clinical setting and, therefore, also in Cancer Registers.
  • The increasing incidence rate of esophageal adenocarcinoma in Sweden is unlikely to be explained by such differences in tumor classification, however.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / classification. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg. 2001 Oct;167(10):748-57 [11775726.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Chirurg. 1987 Jan;58(1):25-32 [3829805.001]
  • [Cites] Ugeskr Laeger. 1987 Jul 6;149(28):1904-9 [3433407.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):374-7 [8472157.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1082-6 [11099062.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):529-35 [10215831.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):786-90 [10328109.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):834-42 [10360663.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • (PMID = 16552198.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1448962
  •  go-up   go-down


23. Schuhmacher C, Novotny A, Ott K, Feith M, Siewert JR: [Lymphadenectomy with tumors of the upper gastrointestinal tract]. Chirurg; 2007 Mar;78(3):203-6, 208-12, 214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Locally advanced Barrett carcinoma is also an indication for classic two-field lymphadenectomy together with abdominothoracic oesophagectomy and creation of a stomach tube with intrathoracic anastomosis.
  • Adenocarcinoma of the cardia and subcardial gastric cancer including the cardia both require lymphadenectomy analogous to that performed in gastric cancer, with special attention paid to the retroperitoneal lymphatic drainage towards the left kidney pedicle.
  • For therapy of gastric cancer, a systematic D2 lymphadenectomy should always be performed.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Lymph Node Excision / methods. Precancerous Conditions / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Cardia / pathology. Cardia / surgery. Esophagectomy / methods. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging. Prognosis. Thoracic Cavity / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Oct;15(4):751-64 [17030271.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Br J Surg. 1998 Jun;85(6):840-4 [9667720.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1576-84 [16317484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):303-8 [15028313.001]
  • [Cites] Chirurg. 2006 Dec;77(12):1095-103 [17119884.001]
  • [Cites] World J Surg. 2005 Jun;29(6):700-7 [16078126.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):905-8 [2804584.001]
  • [Cites] Surg Technol Int. 2006;15:32-6 [17029158.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] Br J Surg. 2002 May;89(5):604-8 [11972551.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] World J Surg. 2006 Feb;30(2):191-8 [16425071.001]
  • [Cites] Hepatogastroenterology. 2004 Jul-Aug;51(58):1015-20 [15239237.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):743-52 [11088069.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1441-9 [16871357.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Chirurg. 2005 Jun;76(6):588-94 [15875146.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):483-90 [15024309.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 17333037.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR: Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol; 2006 Sep 15;94(4):307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction.
  • BACKGROUND: Adenocarcinoma of the esophago-gastric junction (EGJ) potentially spreads to abdominal and mediastinal lymph nodes.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophagogastric Junction. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Barrett Esophagus / pathology. Cardia. Esophageal Neoplasms / mortality. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Risk. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16917878.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Okabayashi T, Kobayashi M, Sugimoto T, Akimori T, Namikawa T, Okamoto K, Maeda H, Araki K: Clinicopathological features of type 1 gastric carcinoma: the need to be cautious of superficial lesion surrounding type 1 gastric carcinoma. Hepatogastroenterology; 2006 Mar-Apr;53(68):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of type 1 gastric carcinoma: the need to be cautious of superficial lesion surrounding type 1 gastric carcinoma.
  • BACKGROUND/AIMS: Gastric carcinoma (GC) is one of the most common malignant tumors of the digestive tract and the incidence of adenocarcinoma of the upper one-third of the stomach has increased recently worldwide.
  • RESULTS: The characteristics of patients with Type 1 GC were different from those of patients with non-Type 1 GC: Their tumors were more often in the upper one-third of the stomach (37% vs. 15%), lesions were histologically differentiated in 80% (vs. 56%), and there were more superficial lesions surrounding Type 1 GC (80% vs. 8%).
  • The current series suggested that Type 1 GC are associated frequently with superficial lesions, making local resections more difficult, and that Type 1 GC was similar clinicopathologically to carcinoma of the gastric cardia and had different etiologies contributed to its tumorgenesis, compared with non-Type 1 GC, and Type 1 GC may become the key which solves the problem of carcinoma at the gastric cardia.
  • [MeSH-major] Carcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608047.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Nagel G, Linseisen J, Boshuizen HC, Pera G, Del Giudice G, Westert GP, Bueno-de-Mesquita HB, Allen NE, Key TJ, Numans ME, Peeters PH, Sieri S, Siman H, Berglund G, Hallmans G, Stenling R, Martinez C, Arriola L, Barricarte A, Chirlaque MD, Quiros JR, Vineis P, Masala G, Palli D, Panico S, Tumino R, Bingham S, Boeing H, Bergmann MM, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Olsen A, Tjonneland A, Trichopoulou A, Bamia C, Soukara S, Sabourin JC, Carneiro F, Slimani N, Jenab M, Norat T, Riboli E, González CA: Socioeconomic position and the risk of gastric and oesophageal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Epidemiol; 2007 Feb;36(1):66-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic position and the risk of gastric and oesophageal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).
  • OBJECTIVES: To evaluate the association of socioeconomic position with adenocarcinoma of the oesophagus and stomach.
  • After an average follow-up of 6.5 years, 268 cases with adenocarcinoma of the stomach and 56 of the oesophagus were confirmed.
  • RESULTS: Higher education was significantly associated with a reduced risk of gastric cancer [vs lowest level of education, hazard ratio (HR): 0.64, 95% Confidence intervals (CI): 0.43-0.98].
  • This effect was more pronounced for cancer of the cardia (HR: 0.42, 95% CI: 0.20-0.89) as compared to non-cardia gastric cancer (HR: 0.66, 95% CI: 0.36-1.22).
  • Additionally, the inverse association of educational level and gastric cancer was stronger for cases with intestinal (extreme categories, HR: 0.13, 95% CI: 0.04-0.44) rather than diffuse histological subtype (extreme categories, HR: 0.71 95% CI: 0.37-1.40).
  • CONCLUSION: A higher socioeconomic position was associated with a reduced risk of gastric adenocarcinoma, which was strongest for cardia cancer or intestinal histological subtype, suggesting different risk profiles according to educational level.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Gastrointestinal Neoplasms / etiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Cardia. Case-Control Studies. Diet. Educational Status. Europe / epidemiology. Female. Humans. Incidence. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / etiology. Life Style. Male. Middle Aged. Prospective Studies. Risk Factors. Sex Distribution. Socioeconomic Factors. Stomach Neoplasms / epidemiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227779.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M: Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg; 2006 Oct;30(10):1864-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach.
  • BACKGROUND: Carcinoma arising in the cardioesophageal junction is a distinct clinical entity compared with tumors located in other regions of the stomach.
  • The prognosis for adenocarcinoma of the upper stomach is considered to be relatively poorer than carcinomas of the more distal stomach.
  • We have therefore investigated patients with carcinoma of the gastric cardia in order to evaluate the underlying cause of this poor prognosis.
  • MATERIALS AND METHODS: Clinicopathologic features and postoperative prognosis of 101 patients with carcinoma of the cardia were evaluated and compared with findings on 1884 patients with tumors in other regions of the stomach.
  • RESULTS: Tumors of the cardia had a mean size of 6.8 cm, which was significantly larger than the mean size of 5.9 cm for tumors found in the middle- and lower third of the stomach.
  • The incidence of serosal invasion, lymph node metastasis, and lymphatic and blood vessel invasion was higher in association with adenocarcinoma of the cardia than with adenocarcinoma in remaining parts of the stomach.
  • In the analysis of patients who had undergone curative resection, the 5-year survival rates were 61.6, 79.1, and 82.6% in patients with carcinoma of the cardia, upper one-third, and remaining middle- and lower one-third of the stomach, respectively, and the differences were statistically significant.
  • Multivariate analysis indicated that adenocarcinoma of the gastric cardia is an independent prognostic factor.
  • With regard to the site of recurrence, both lymph node and hematogenous recurrence were observed more frequently in the cardia than in the remaining parts of the stomach.
  • CONCLUSIONS: Our data indicate that the prognosis of patients with adenocarcinoma of the gastric cardia is extremely poor.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Gastric Fundus. Neoplasm Recurrence, Local / epidemiology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] Surg Oncol. 1995;4(2):75-81 [7551262.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):569-74 [1623472.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):514-9 [7960222.001]
  • [Cites] Jpn J Surg. 1989 May;19(3):290-5 [2779027.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Natl Med Assoc. 1995 Jun;87(6):423-6 [7595964.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16983479.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J, Asia-Pacific Gastric Cancer Consensus Conference: Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol; 2008 Mar;23(3):351-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asia-Pacific consensus guidelines on gastric cancer prevention.
  • BACKGROUND AND AIM: Gastric cancer is a major health burden in the Asia-Pacific region but consensus on prevention strategies has been lacking.
  • We aimed to critically evaluate strategies for preventing gastric cancer.
  • RESULTS: Helicobacter pylori infection is a necessary but not sufficient causal factor for non-cardia gastric adenocarcinoma.
  • A high intake of salt is strongly associated with gastric cancer.
  • Fresh fruits and vegetables are protective but the use of vitamins and other dietary supplements does not prevent gastric cancer.
  • Host-bacterial interaction in H. pylori infection results in different patterns of gastritis and differences in gastric acid secretion which determine disease outcome.
  • A positive family history of gastric cancer is an important risk factor.
  • Low serum pepsinogens reflect gastric atrophy and may be useful as a marker to identify populations at high risk for gastric cancer. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high-risk populations. H. pylori screening and treatment is most effective before atrophic gastritis has developed.
  • It does not exclude the existing practice of gastric cancer surveillance in high-risk populations.
  • In populations at low risk for gastric cancer, H. pylori screening is not recommended.
  • CONCLUSION: A strategy of H. pylori screening and eradication in high-risk populations will probably reduce gastric cancer incidence, and based on current evidence is recommended by consensus.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Biomarkers, Tumor / analysis. Helicobacter Infections / drug therapy. Helicobacter pylori. Mass Screening. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318820.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Pepsinogens; 0 / Sodium Chloride, Dietary; 0 / Vitamins; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 140
  •  go-up   go-down


29. Parfitt JR, Miladinovic Z, Driman DK: Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002. Can J Gastroenterol; 2006 Apr;20(4):271-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002.
  • BACKGROUND: The increasing incidence of esophageal and proximal gastric (cardia) adenocarcinoma and the decreasing incidence of distal gastric (antropyloric) adenocarcinoma has been documented in several populations.
  • Number of cases and rates per 100,000 age-adjusted to the 1996 Canadian standard, were obtained for all esophageal and gastric carcinoma cases reported between 1964 and 2002.
  • RESULTS: The incidence of adenocarcinoma of the distal esophagus increased in men and women (average annual increase of 9.5% in men; 4.3% in women).
  • The incidence of adenocarcinoma of the cardia increased in men and women (average annual increase of 7.3% in men; 5.8% in women).
  • The incidence of antropyloric adenocarcinoma increased in men and women (average annual increase of 4.4% in men; 5.3% in women).
  • CONCLUSIONS: There has been a significant increase in the incidence of adenocarcinoma around the gastroesophageal junction in men over the 39-year study period.
  • The increase in incidence of distal gastric adenocarcinoma is unexpected and may relate to a reclassification phenomenon, immigration trends in Ontario and a rising incidence of diffuse/signet ring cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Esophagogastric Junction. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1082-6 [11099062.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):290 [15737017.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Can J Public Health. 2004 Jan-Feb;95(1):16-20 [14768735.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] BMJ. 2004 Aug 21;329(7463):420 [15321897.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):275-8 [1467774.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):411-5 [7841063.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Prev Med. 1997 Jul-Aug;26(4):534-41 [9245676.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Health Rep. 1998 Spring;9(4):31-7(Eng); 31-8(Fre) [9836878.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Apr;13(4):356-62 [9641297.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • (PMID = 16609756.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2659904
  •  go-up   go-down


30. Zhang XF, Wang YM, Wang R, Wei LZ, Li Y, Guo W, Wang N, Zhang JH: [Correlation of E-cadherin polymorphisms to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. Ai Zheng; 2005 May;24(5):513-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of E-cadherin polymorphisms to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
  • This study was designed to investigate the correlation of CDH1 C-160A and G-347GA single nucleotide polymorphisms(SNPs) to susceptibilities and lymphatic metastases of esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in northern China population.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Alleles. Cardia. Female. Genetic Predisposition to Disease. Genotype. Humans. Lymphatic Metastasis. Male. Middle Aged. Polymorphism, Single Nucleotide


31. Tsavaris N, Kosmas C, Kopterides P, Tsikalakis D, Skopelitis H, Sakelaridi F, Papadoniou N, Tzivras M, Balatsos V, Koufos C, Archimandritis A: Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J Gastroenterol; 2005 Dec 7;11(45):7174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma.
  • AIM: To determine the serum levels of c-reactive protein (CRP), transferrin (TRF), a2-macroglobulin (A2M), ceruloplasmin (CER), a1-acid glycoprotein (AAG), pre-albumin (P-ALB) and retinol-binding protein (RBP) in gastric carcinoma patients and to explore their possible correlation with underlying Helicobacter pylori (H pylori) infection.
  • METHODS: We measured the serum levels of CRP, TRF, A2M, CER, AAG, P-ALB, and RBP in 153 preoperative patients (93 males; mean age: 63.1+/-11.3 years) with non-cardia gastric adenocarcinoma and 19 healthy subjects.
  • Retinol-binding protein seems to discriminate between infected and non-infected patients with gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437667.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers, Tumor; 0 / Retinol-Binding Proteins
  • [Other-IDs] NLM/ PMC4725071
  •  go-up   go-down


32. Huerta JM, Navarro C, Chirlaque MD, Tormo MJ, Steindorf K, Buckland G, Carneiro F, Johnsen NF, Overvad K, Stegger J, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Boeing H, Kaaks R, Rohrmann S, Vigl M, Lagiou P, Trichopoulos D, Trichopoulou A, Bas Bueno-de-Mesquita H, Monninkhof EM, Numans ME, Peeters PH, Mattiello A, Pala V, Palli D, Tumino R, Vineis P, Agudo A, Ardanaz E, Arriola L, Molina-Montes E, Rodríguez L, Lindkvist B, Manjer J, Stenling R, Lund E, Crowe FL, Key TJ, Khaw KT, Wareham NJ, Jenab M, Norat T, Romaguera D, Riboli E, González CA: Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort. Cancer Causes Control; 2010 May;21(5):657-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort.
  • OBJECTIVE: To analyse the association between types of physical activity (occupational, recreational and household, vigorous and overall) and risk of primary oesophageal (OAC) or gastric adenocarcinoma (GAC).
  • Analyses were repeated by tumour site (cardia/non-cardia) and histological type (intestinal/diffuse).
  • A lower risk of overall and non-cardia GAC was found for increasing levels of a PA index which combined occupational PA with weekly time spent in sports and cycling.
  • The hazard ratio (HR) of GAC was 0.69, 95% CI: 0.50-0.94, for the comparison between active and inactive participants according to the PA index (HR = 0.44, 95% CI:0.26-0.74, for non-cardia GAC).
  • No effect was found for cardia tumours or histological subtypes of GAC.
  • CONCLUSIONS: Overall and distal (non-cardia) gastric tumours were inversely associated with time spent on cycling and sports and a total PA index.
  • No association was found for any type of PA and risk of cardia cancers of the stomach.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Exercise. Health Behavior. Nutrition Surveys. Stomach Neoplasms / epidemiology


33. van Vliet EP, van der Lugt A, Kuipers EJ, Tilanus HW, van der Gaast A, Hermans JJ, Siersema PD: Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol; 2007 Sep 1;96(3):200-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study.
  • Aim was to compare US, US plus fine-needle aspiration (US-FNA), CT, US + CT, and US-FNA + CT for the detection of these metastases in esophageal or gastric cardia cancer patients.
  • METHODS: Between 1994 and 2004, 567 patients underwent US and CT for esophageal or gastric cardia cancer staging.
  • CONCLUSION: US-FNA seems the preferred diagnostic modality for the detection of supraclavicular lymph node metastases in patients with esophageal or gastric cardia cancer.
  • [MeSH-major] Esophageal Neoplasms / pathology. Lymph Nodes / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Carcinoma, Squamous Cell / pathology. Cardia / pathology. Databases as Topic. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2007 Sep 1;96(3):192-3 [17674366.001]
  • (PMID = 17455243.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Goto Y, Ando T, Naito M, Goto H, Hamajima N: Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population. World J Gastroenterol; 2006 Oct 21;12(39):6361-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population.
  • AIM: To examine the association of inducible nitric oxide synthase (iNOS) C150T polymorphism with gastric cancer, as well as with gastric atrophy and H pylori seropositivity.
  • METHODS: A single nucleotide polymorphism of iNOS C150T was examined for 454 Japanese health checkup examinees (126 males and 328 females) aged 35 to 85 years without a history of cancer and 202 gastric cancer patients (134 males and 68 females) aged 33 to 94 years with pathologically confirmed diagnosis of gastric adenocarcinoma.
  • RESULTS: The iNOS C150T polymorphism was not associated with gastric atrophy or with H pylori seropositivity.
  • The odds ratio (OR) of the C/T + T/T for gastric cancer was increased without statistical significance (OR = 1.19, 95% confidence interval (CI): 0.68-2.08).
  • In the differentiated subgroup (n = 113), however, the OR of the C/T genotype for gastric cancer was significant (OR = 2.02, 95% CI: 1.04-3.92) relative to the C/C genotype.
  • In addition, considering the location of gastric cancer (n = 105), there were significant differences between the controls and non-cardia group with the OR of 2.13 (95% CI: 1.08-4.18) for C/T and 1.94 (95% CI: 1.00-3.78) for C/T + T/T.
  • CONCLUSION: The iNOS C150T polymorphism is associated with the risk of H pylori-related gastric cancer in a Japanese population.
  • This polymorphism may play an important role in increasing the risk of gastric cancer in Asian countires with the highest rates of gastric cancer.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Nitric Oxide Synthase Type II / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] Helicobacter. 2001 Dec;6(4):294-9 [11843961.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4692-700 [11971019.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30589-95 [10521442.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):197-202 [15617837.001]
  • [Cites] J Biol Chem. 2005 Jan 28;280(4):2409-12 [15548540.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2454-6 [16214932.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):203-8 [16032704.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):649-55 [12370666.001]
  • [Cites] Lancet. 2002 Nov 9;360(9344):1468-75 [12433515.001]
  • [Cites] Amino Acids. 2004 Jul;26(4):321-9 [15290337.001]
  • [Cites] Gut. 2004 Sep;53(9):1250-5 [15306579.001]
  • [Cites] World J Gastroenterol. 2004 Nov 15;10(22):3278-83 [15484300.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Gastroenterology. 1990 Nov;99(5):1543-4 [2264888.001]
  • [Cites] J Exp Med. 1992 Aug 1;176(2):599-604 [1380065.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1260-6 [1397883.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):297-301 [7505200.001]
  • [Cites] Mutat Res. 1994 Mar 1;305(2):253-64 [7510036.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 27;219(3):784-8 [8645258.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Free Radic Res. 1996 Jun;24(6):439-50 [8804987.001]
  • [Cites] Clin Genet. 1997 Sep;52(3):192-3 [9377812.001]
  • [Cites] Gene. 1997 Dec 19;204(1-2):165-70 [9434180.001]
  • [Cites] Lancet. 1998 Jan 24;351(9098):265-6 [9457101.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):408-11 [9529506.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2792-6 [11397889.001]
  • (PMID = 17072962.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4088147
  •  go-up   go-down


35. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol; 2009 Feb 20;27(6):851-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.
  • PURPOSE: Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma.
  • PATIENTS AND METHODS: Patients with locally advanced (uT3-4NXM0) adenocarcinoma of the lower esophagus or gastric cardia were randomly allocated to one of two treatment groups: induction chemotherapy (15 weeks) followed by surgery (arm A); or chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 20;27(6):836-7 [19139425.001]
  • (PMID = 19139439.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Shen H, Newmann AS, Hu Z, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wang X, Wei Q: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep; 2005 Feb;13(2):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China.
  • Studies have suggested that low dietary folate intake is associated with an increased risk of gastric cancer.
  • C677T, A1298C and G1793A) and their haplotypes are associated with the risk of gastric cancer.
  • To test this hypothesis, we genotyped these polymorphisms in a population-based case-control study of 320 incident gastric adenocarcinoma cases and 313 cancer-free controls in a Chinese population.
  • Consistent with our previous observations, the 677TT genotype was associated with a significantly increased risk for gastric cancer (adjusted OR =1.79, 95% CI =1.02-3.15) compared with the 677CC genotype; the association was more evident for gastric cardia adenocarcinoma (adjusted OR =2.60, 95% CI =1.30-5.21).
  • When we used the haplotype analyses and assumed MTHFR 677T, 1298C and 1793A as risk alleles, individuals with 6 variant alleles had a significantly (4.64-fold) increased risk for gastric cardia adenocarcinoma (OR =4.64, 95% CI =1.34-16.01) compared with those having 0-2 variants.
  • These findings suggest that the MTHFR common variants and their haplotypes may play a role in the etiology of gastric cancer, particularly gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Asian Continental Ancestry Group / genetics. Cardia. Case-Control Studies. China / epidemiology. Female. Gene Frequency. Genetic Predisposition to Disease. Haplotypes. Humans. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643524.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


37. Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G: Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol; 2010;2010:721485
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma.
  • AIM: Investigate the promoter methylation of the Thrombospondin-1 (TSP1) gene in gastric cardia adenocarcinoma (GCA).
  • [MeSH-major] Adenocarcinoma / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Thrombospondin 1 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2003 Jan 15;116(Pt 2):217-24 [12482908.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):509-19 [11980922.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6299-310 [14559817.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):245-58 [15036264.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):961-8 [15094109.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Jan;68(1):240-3 [5276296.001]
  • [Cites] Blood. 1985 Jan;65(1):79-84 [3965054.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):1059-70 [4030891.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):719-27 [2493001.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):755-61 [2714880.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2899-903 [8428963.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):923-32 [8349738.001]
  • [Cites] Int J Cancer. 1994 Oct 15;59(2):191-5 [7927918.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6504-11 [7527299.001]
  • [Cites] J Cell Sci. 1995 Feb;108 ( Pt 2):797-809 [7539439.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1183-91 [8751720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1793-801 [9528751.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):3534-41 [16951312.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3112-20 [16835379.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5930-9 [17442977.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):14-21 [18425817.001]
  • [Cites] Cell. 2008 Aug 8;134(3):392-404 [18692464.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7090-9 [18757424.001]
  • [Cites] Curr Drug Targets. 2008 Oct;9(10):842-50 [18855618.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):2947-54 [10706681.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):597-614 [11102749.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2427-36 [11160302.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Oncology. 2003;64(4):423-9 [12759541.001]
  • (PMID = 20300551.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thrombospondin 1
  • [Other-IDs] NLM/ PMC2838370
  •  go-up   go-down


38. Nyrén O, Blot WJ: Helicobacter pylori infection: mainly foe but also friend? J Natl Cancer Inst; 2006 Oct 18;98(20):1432-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / microbiology. Cardia. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • (PMID = 17047185.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


39. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


40. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol; 2010 Dec 10;28(35):5210-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
  • PURPOSE: Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy.
  • PATIENTS AND METHODS: Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone.
  • RESULTS: This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III.
  • Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Neoadjuvant Therapy / methods. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cardia / pathology. Cardia / surgery. Combined Modality Therapy. Digestive System Surgical Procedures. Disease-Free Survival. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] JAMA. 2010 May 5;303(17):1729-37 [20442389.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):423-9 [12836016.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1248-52 [7552009.001]
  • [Cites] J Infus Chemother. 1996 Summer;6(3):123-6 [9229322.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2580-5 [17577037.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5062-7 [19770374.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):139-44 [10761793.001]
  • (PMID = 21060024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004099
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10-CA11488-29
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3020693
  •  go-up   go-down


41. Kamangar F, Qiao YL, Schiller JT, Dawsey SM, Fears T, Sun XD, Abnet CC, Zhao P, Taylor PR, Mark SD: Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China. Int J Cancer; 2006 Aug 1;119(3):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China.
  • Each year, esophageal and gastric cancers cause more than 900,000 deaths worldwide.
  • We conducted a large prospective study to examine the association between serum antibodies to HPV 16, HPV 18 and HPV 73 and subsequent development of esophageal squamous cell carcinoma (ESCC), gastric cardia adenocarcinoma (GCA), and gastric noncardia adenocarcinoma (GNCA) in a high-risk population for these cancers in Linxian, China.
  • The results of this study do not support a major role for HPV 16, HPV 18 and HPV 73 in the etiology of esophageal and gastric cancers in Linxian, China.
  • [MeSH-major] Antibodies, Viral / blood. Esophageal Neoplasms / etiology. Papillomavirus Infections / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16496409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


42. Ryan AM, Rowley SP, Fitzgerald AP, Ravi N, Reynolds JV: Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity. Eur J Cancer; 2006 May;42(8):1151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity.
  • Recent evidence links obesity with the rising incidence of oesophageal adenocarcinoma.
  • In Ireland between 1995 and 2004 the incidence of oesophageal adenocarcinoma increased by 38%, and this coincided with a 67% increase in the prevalence of obesity.
  • In this study, a prospective case-control study was undertaken in 760 patients presenting to a tertiary centre between 1994 and 2004 diagnosed with cancer of the oesophagus, gastric cardia or stomach.
  • Based on pre-illness BMI, 82% of patients who developed adenocarcinoma of the oesophagus were either overweight or obese compared with 59% of the healthy control population (P<0.001).
  • A dose-dependent relationship existed between BMI and oesophageal adenocarcinoma in males.
  • Using common cut-off points for BMI, the OR of adenocarcinoma of the lower oesophagus was 11.3 times higher (95% CI: 3.5-36.4) for individuals with a BMI >30 kg/m2 versus individuals with a BMI <22 kg/m2 (P<0.001 for trend).
  • For adenocarcinoma of the gastric cardia, males in the top quartile of BMI had an OR of 3.5 (95% CI: 1.3-9.4) compared with the lowest quartile (P=0.03 for trend).
  • The odds ratio for adenocarcinoma of the oesophagus, the oesophago-gastric junction and gastric cardia rose significantly with increasing BMI.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Cardia. Esophageal Neoplasms / etiology. Obesity / complications. Stomach Neoplasms / etiology


43. Sarbia M: The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens. Virchows Arch; 2006 May;448(5):532-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens.
  • The current study was performed to determine whether the histopathological appearance of oesophageal adenocarcinoma (AC) differs significantly from that of cardiac or gastric AC.
  • Therefore, HE-stained slides of 215 primarily resected oesophageal AC, 108 cardiac and 184 gastric AC were classified according to a variety of clinico-pathologic parameters.
  • According to Lauren's classification, oesophageal AC (1.4%) less frequently belonged to the diffuse type than cardiac (2.8%) and gastric AC (23.9%; p<0.0001).
  • Tubular and papillary AC, as defined by the WHO classification, were more frequent among oesophageal (94.4%) than among cardiac (87.0%) and gastric AC (59.2%; p<0.0001).
  • Solid carcinomas, according to Carneiro's classification, were less frequent among oesophageal (2.8%) than among cardiac (10.2%) and gastric AC (9.2%; p<0.0001).
  • Oesophageal AC were graded more frequently G1/G2 (53.9%) than cardiac (30.6%) and gastric AC (27.7%; p<0.0001).
  • In conclusion, oesophageal AC displays the same histological spectrum as cardiac and gastric AC.
  • However, the relative proportion of differentiated, gland-forming carcinomas is significantly more frequent in the oesophagus than in the cardia and in the stomach.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Esophageal Neoplasms / classification. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):444-9 [15297937.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):224-8 [15197775.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):333-6 [7729944.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):95-9 [8270616.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):348-50 [11097357.001]
  • [Cites] Am J Surg. 1985 Sep;150(3):365-9 [4037198.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):183-91 [7832278.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1040-6 [12917759.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):33-40 [11141476.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):505-12 [14629106.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2429-37 [10861416.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • (PMID = 16498532.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


44. Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein A, Taylor P: Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer; 2009 Aug 05;9:269
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China.
  • METHODS: 600 esophageal squamous cell carcinoma (ESCC) cases, 598 gastric cardia adenocarcinoma cases, and 316 gastric non-cardia adenocarcinoma cases, and 1514 age-, gender-, and neighborhood-matched controls were asked for FH in first degree relatives and non-blood relatives.
  • FH of gastric cardia cancer was associated with an increased risk of all three cancers.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1991;27(10):1336 [1835609.001]
  • [Cites] Am J Hum Genet. 2000 Jul;67(1):110-9 [10841811.001]
  • [Cites] Jpn J Cancer Res. 1992 Jun;83(6):568-75 [1644660.001]
  • [Cites] Int J Epidemiol. 1992 Oct;21(5):877-82 [1468848.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):195-202 [8318635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):15-8 [8118379.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):775-80 [8206671.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):387-92 [7920205.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):593-600 [7677173.001]
  • [Cites] Jpn J Cancer Res. 1996 Oct;87(10):1025-8 [8957058.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1159-65 [9447394.001]
  • [Cites] Int J Cancer. 1998 May 18;76(4):468-71 [9590119.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):801-5 [9626344.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1997 Oct;18(5):275-8 [9812488.001]
  • [Cites] Am J Epidemiol. 1999 Mar 1;149(5):454-62 [10067905.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3548-54 [15867347.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1390-3 [15941946.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):148-52 [11391635.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):688-94 [11807799.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S1-6 [11821780.001]
  • [Cites] Gut. 2002 Sep;51(3):323-8 [12171951.001]
  • [Cites] J Clin Gastroenterol. 2003 Jan;36(1):30-3 [12488704.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):214-8 [12532434.001]
  • [Cites] Eur J Cancer Prev. 2003 Jun;12(3):183-9 [12771555.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3872-6 [12873975.001]
  • [Cites] Int J Epidemiol. 2003 Aug;32(4):579-83 [12913033.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):240-4 [15019915.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1402-6 [15054463.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1250-7 [15233662.001]
  • [Cites] Sci Sin. 1975 Jan-Feb;18(1):131-48 [1145176.001]
  • [Cites] Cancer. 1985 Oct 15;56(8):2112-6 [4027937.001]
  • [Cites] Chin Med J (Engl). 1985 Oct;98(10):749-52 [3938702.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):755-61 [2714880.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2268-74 [2317814.001]
  • [Cites] Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):584-9 [2119361.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 1990 Dec;70(12):679-81, 46 [1963371.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):565-76 [16083713.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1047-51 [16570268.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):1023-32 [16843873.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1271-83 [17030196.001]
  • [Cites] Fam Cancer. 2006;5(4):343-52 [16724246.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Jun;151(1):17-20 [17690734.001]
  • [Cites] World J Gastroenterol. 2007 Nov 21;13(43):5760-4 [17963305.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1857-63 [18475303.001]
  • [Cites] JAMA. 2008 Jun 4;299(21):2515-23 [18523220.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1429-32 [18567000.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R47 [18507837.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4787-93 [18676749.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1205-13 [11002214.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3476-82 [10589761.001]
  • [Cites] J Natl Cancer Inst. 1992 May 20;84(10):771-6 [1573663.001]
  • (PMID = 19656375.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2729777
  •  go-up   go-down


45. DeMeester SR: Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol; 2006 Jan;13(1):12-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.
  • Previously rare, adenocarcinoma of the esophagus and gastroesophageal junction is now the most common esophageal cancer, and in the United States the incidence is increasing faster than that of any other malignancy.
  • Surveillance in patients with Barrett's esophagus is identifying adenocarcinoma at an earlier, more curable stage in many patients, and at the same time new endoscopic and surgical options are available for the therapy of these localized tumors.
  • METHODS: This article is a review of the epidemiology, diagnosis, staging, and treatment options for esophageal and gastroesophageal junction adenocarcinoma.
  • RESULTS: The epidemiology, prognosis, patterns of lymphatic metastasis, and survival for esophageal and gastroesophageal junction adenocarcinoma suggest that these tumors are similar.
  • CONCLUSIONS: Surveillance programs for Barrett's are identifying patients with early, curable adenocarcinoma of the esophagus or gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378161.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 163
  •  go-up   go-down


46. Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB: Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology; 2005 May-Jun;52(63):944-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer.
  • BACKGROUND/AIMS: Abnormal function of gene p53 is associated with the formation of various cancers including gastric cancer.
  • In this study, we evaluated the risk factors associated with p53 codon 72 polymorphism and gastric cancer carcinogenesis.
  • The proline homozygote was more frequent in the patients with gastric cancer at the cardia than in those with cancer at the antral or corpus locations. (55.56% of cardia vs. 14.28% of corpus and antrum, p=0.024).
  • The arginine allele was associated with antral and corpus location of gastric cancer and the proline allele was associated with cardial location (OR=3.25, p=0.026).
  • CONCLUSIONS: The proline allele at p53 codon 72 is associated with adenocarcinoma of the gastric cardia, and the arginine allele is associated with cancer of the antral and corpus locations.
  • These findings suggest that different genotypes of the p53 gene in different locations of stomach might implicate a different cause of tumor growth.
  • [MeSH-major] Alleles. Arginine / genetics. Cardia. Codon. Gastric Fundus. Genes, p53 / genetics. Polymorphism, Single Nucleotide. Proline / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966238.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


47. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S: The prognosis of gastric cardia cancer after R0 resection. Am J Surg; 2010 Jun;199(6):725-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of gastric cardia cancer after R0 resection.
  • BACKGROUND: The aim of this study was to evaluate the prognosis of gastric cardia cancers in comparison with other gastric cancers.
  • METHODS: The medical records of 251 patients with gastric cardia cancers and 6568 patients with other gastric cancers who underwent R0 resection were reviewed.
  • RESULTS: Gastric cardia cancer was associated with more advanced staging and less favorable clinicopathologic features at diagnosis compared with other gastric cancers.
  • The overall 5-year survival rates were 79.7% and 84.6% in patients with cardia cancer and other cancers, respectively.
  • CONCLUSIONS: Although patients with gastric cardia cancers are diagnosed at an advanced stage, the long-term survival rates are similar to those with other gastric cancers.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19837398.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Xu DK, Zhao P, Wang CF, Shao YF, Lin HW, Tian YT: [Clinicopathological characteristics and prognosis of remnant stomach cancer--report of 45 cases]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):852-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristics and prognosis of remnant stomach cancer--report of 45 cases].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognostic factors of remnant stomach cancer.
  • METHODS: The clinicopathological and prognosis data of 45 patients with remnant stomach cancer were retrospectively analyzed.
  • RESULTS: The remnant stomach cancer are likely to develop in males with a ratio of male to female: 44:1.
  • The interval from the initial operation to the diagnosis of remnant stomach cancer was 5 to 42 years with an average of 23 years.
  • Of these 45 patients, 28 had lesion at anastomotic site, 9 in the gastric cardia and 8 in other locations; 19 had radical resection, 16 palliative resection and 10 exploration alone except one who had an anastomosis of remnant stomach with the jejunum.
  • The histology types included: 1 un-differentiated adenocarcinoma, 36 poorly-differentiated adenocarcinoma, 7 moderately-differentiated adenocarcinoma and 1 well-differentiated adenocarcinoma.
  • CONCLUSION: Remnant stomach cancer prevalently occurs in the male usually 10 years after Birroth II gastrectomy.
  • Poorly-differentiated adenocarcinoma is found to be the prevalent histological type of advanced remnant stomach cancer.
  • The prognosis of remnant stomach cancer is correlated with pTNM stage and whether having been treated with complete resection or not.
  • Patients with early remnant stomach cancer may survive for a long time if radical resection can be done.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Gastric Stump / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416009.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ: Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol; 2005 Jul;58(7):722-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
  • BACKGROUND: It is sometimes difficult to distinguish between cardia cancer and oesophageal cancer.
  • METHODS: Consecutive patients with a malignant tumour in the oesophagus or stomach were recruited.
  • RESULTS: Endoscopically located adenocarcinoma of the oesophagus was present in 84 patients (64 men, 20 women; mean age, 68 years; range, 44-91).
  • Cancer located primarily in the gastric cardia was present in 63 patients (42 men, 21 women; mean age, 68 years; range, 42-88).
  • The histological diagnosis was metastasis from a primary tumour outside the oesophagus or stomach in 19 patients.
  • Patients in group A had definite oesophageal cancer, group B patients had a definite carcinoma located in the gastric cardia, and group C patients had an obstructing tumour distal in the oesophagus at the level of the diaphragm, which could not be passed with the endoscope.
  • CONCLUSION: CK phenotyping cannot distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cardia. Esophageal Neoplasms / diagnosis. Keratins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):445-54 [11962749.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Neth J Med. 2003 Jan;61(1):14-8 [12688564.001]
  • [Cites] Histopathology. 2003 Aug;43(2):127-34 [12877727.001]
  • [Cites] Pathol Res Pract. 2003;199(9):581-7 [14621193.001]
  • [Cites] Histopathology. 2003 Nov;43(5):453-61 [14636271.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):371-6 [15017595.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):487-94 [9309399.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):820-31 [11857318.001]
  • (PMID = 15976339.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770716
  •  go-up   go-down


50. Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J: Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer; 2006 Jan 16;94(1):136-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.
  • Oesophageal and gastric adenocarcinoma share an unexplained male predominance, which would be explained by the hypothesis that oestrogens are protective in this respect.
  • We carried out a nested case-control study of hormone replacement therapy (HRT) among 299 women with oesophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women, frequency matched by age and calendar year in the General Practitioners Research Database in the United Kingdom.
  • Among 1 619 563 person-years of follow-up, more than 50% reduced risk of gastric adenocarcinoma was found among users of HRT compared to nonusers (odds ratio (OR), 0.48, 95% confidence interval (CI) 0.29-0.79).
  • This inverse association appeared to be stronger for gastric noncardia (OR 0.34, 95% CI 0.14-0.78) and weaker for gastric cardia tumours (OR 0.68, 95% CI 0.23-2.01).
  • There was no association between HRT and oesophageal adenocarcinoma (OR 1.17, 95% CI 0.41-3.32).
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Hormone Replacement Therapy. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] J Chronic Dis. 1980;33(10):595-605 [7410520.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1980 Dec;65(6):1201-7 [7001123.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5181-2 [7139622.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] BMJ. 1991 Mar 30;302(6779):766-8 [2021768.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):66-9 [2044927.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):259-64 [1467771.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Gut. 1993 Dec;34(12):1672-6 [8282253.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] IARC Sci Publ. 1997;(138):325-9 [9353673.001]
  • [Cites] Br J Clin Pharmacol. 1998 May;45(5):419-25 [9643612.001]
  • [Cites] Surg Today. 1998;28(10):1007-14 [9786571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4886-94 [10499548.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):341-5 [11487262.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):319-24 [12073050.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] JAMA. 2002 Aug 21;288(7):872-81 [12186605.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):686-9 [12741446.001]
  • (PMID = 16404367.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361087
  •  go-up   go-down


51. Créhange G, Bonnetain F, Chauffert B, Rat P, Bedenne L, Maingon P: [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?]. Cancer Radiother; 2008 Sep;12(5):365-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?].
  • Adenocarcinoma of the oesophagogastric junction has an ominous prognosis.
  • Until now, oesophageal adenocarcima care was close to the squamous cell cancer one whereas adenocarcinoma of the cardia was mixed with gastric cancers.
  • Results from several phase-III studies or meta-analysis allowed to define three therapeutic strategies applicable to adenocarcinoma of the oesophagus and the oesophagogastric junction.
  • We have performed a review of the literature with a methodological analysis of data with a high level of evidence in order to advise perioperative treatment guidelines for patients with a resectable adenocarcinoma of the lower oesophagus or gastro-oesophageal junction.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Postoperative Care. Preoperative Care. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18420440.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 59
  •  go-up   go-down


52. Bhurgri Y, Pervez S, Kayani N, Haider S, Ahmed R, Usman A, Bashir I, Bhurgri A, Hasan SH, Zaidi SM: Rising incidence of gastric malignancies in Karachi, 1995- 2002. Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):41-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising incidence of gastric malignancies in Karachi, 1995- 2002.
  • INTRODUCTION: South Asia is an enigma for gastric cancer, a low risk region with a contradictory high prevalence for Helicobacter pylori.
  • PATIENTS AND METHODS: To examine the demographics, pathology and trends of gastric cancer in Pakistan, epidemiological data of 335 gastric malignancies, registered at Karachi Cancer Registry (KCR) for Karachi South (KS), during 1st January 1995 to 31st December 2002 were reviewed.
  • RESULTS: Ninety six cases of gastric cancers were registered in the 1995-7 period, 61 in males and 35 in females.
  • In the 1998-02 period 239 cases of gastric cancer were registered, 156 cases in males and 83 in females.
  • The majority of the cases presented as poorly or moderately differentiated distal (non-cardia) cancers with a regional spread.
  • CONCLUSION: Gastric cancers in Karachi fall into the prototype of a low risk developing country pattern.
  • Larger pathology-based studies are required to comment on the precise morphological sub-types of gastric adenocarcinoma.
  • Etiological studies focused on different strains of H. pylori are required to address the gastric cancer enigma, whilst examining possible protective environmental or genetic factors.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469622.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


53. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF Jr, El-Omar EM: A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology; 2007 Mar;132(3):905-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors.
  • The TLR4+896A>G polymorphism linked with impaired reactivity to bacterial lipopolysaccharide may play a role in gastric carcinogenesis.
  • METHODS: We assessed associations with premalignant gastric changes in 149 relatives of gastric cancer patients, including 45 with hypochlorhydria and gastric atrophy.
  • We also genotyped 2 independent Caucasian population-based case-control studies of upper gastrointestinal tract cancer, initially in 312 noncardia gastric carcinoma cases and 419 controls and then in 184 noncardia gastric carcinomas, 123 cardia carcinomas, 159 esophageal cancers, and 211 frequency-matched controls.
  • RESULTS: TLR4+896G carriers had an 11-fold (95% confidence interval [CI], 2.5-48) increased odds ratio (OR) for hypochlorhydria; the polymorphism was unassociated with gastric acid output in the absence of H pylori infection.
  • Carriers also had significantly more severe gastric atrophy and inflammation.
  • Seventeen percent of gastric carcinoma patients in the initial study and 15% of the noncardia gastric carcinoma patients in the replication study had 1 or 2 TLR4 variant alleles vs 8% of both control populations (combined OR = 2.3; 95% CI = 1.6-3.4).
  • In contrast, prevalence of TLR4+896G was not significantly increased in esophageal squamous cell (2%, OR = 0.2) or adenocarcinoma (9%, OR = 1.4) or gastric cardia carcinoma (11%, OR = 1.4).
  • CONCLUSIONS: Our data suggest that the TLR4+896A>G polymorphism is a risk factor for noncardia gastric carcinoma and its precursors.
  • [MeSH-major] Carcinoma / genetics. Helicobacter Infections / microbiology. Helicobacter pylori. Polymorphism, Genetic. Precancerous Conditions / genetics. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324405.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CZB/4/485; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  •  go-up   go-down


54. Ridereau-Zins C, Lebigot J, Moubarak E, Hamy A, Azoulay R, Aubé C: [Postoperative imaging of the cardia and stomach]. J Radiol; 2009 Jul-Aug;90(7-8 Pt 2):937-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative imaging of the cardia and stomach].
  • [Transliterated title] Imagerie post-opératoire du cardia et de l'estomac.
  • In addition to treatment of complications from peptic ulcer disease, gastroesophageal reflux and gastric cancer, bariatric surgical procedures have increased over the recent years.
  • Complications after gastric surgery are imaged with upper gastrointestinal contrast studies and CT.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Cardia / surgery. Fundoplication. Gastrectomy. Gastroesophageal Reflux / surgery. Gastroplasty. Postoperative Complications / radiography. Stomach / surgery. Stomach Neoplasms / radiography. Stomach Neoplasms / surgery. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Anastomosis, Surgical / adverse effects. Contrast Media. Gastric Bypass. Gastric Fistula / etiology. Gastroenterostomy. Humans. Lymph Node Excision. Male. Pancreas / surgery. Spleen / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752832.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 30
  •  go-up   go-down


55. Jovanović I, Alempijević T, Milosavljević T, Popović D, Bjelović M, Micev M, Pesko P: [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients]. Srp Arh Celok Lek; 2009 May-Jun;137(5-6):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients].
  • INTRODUCTION In the past two decades, the increased frequency of distal esophageal adenocarcinoma, esophagogastric junction and proximal gastric adenocarcinoma has been observed.
  • The vast majority of these tumours are diagnosed in advanced stages, when the prognosis is poorer than in other gastric cancers.
  • OBJECTIVE: The aim of our study was to analyze the demographic and clinicopathological characteristics of patients operated on for Barrett's, cardia and distal gastric adenocarcinomas, as well as to study the influence of manifestations of each cancerogenetic indication on the studied clinicopathological parameters and to analyze the 5-year survival rate of patients surgically treated for cardia adenocarcinoma in relation to the patients operated on for distal gastric adenocarcinoma.
  • In the patients operated on for Barrett's and cardia cancers, the tumours invaded more deeply the wall layers, i.e. they were significantly more invasive than the distal gastric tumour.
  • The lymph node involvement was present in 87.5% of patients with Barrett's cancer, in 80% with cardia cancer and in 87% with distal gastric cancer.
  • The 3-year survival rate of patients operated on for cardia cancer was 47.4% and the 5-year survival rate was 31.6%, while the 3-year survival rate of patients operated on for distal gastric cancer was 46.2% and the 5-year survival rate was 34.6%.
  • CONCLUSION: At the time of diagnosis cardia cancer and cancers developed at the location of the Barrett's oesophagus, developed significant deeper per continuitatem than gastric cancer.
  • There were no other differences in regard to the analyzed clinicopathological parameters among the tumours of these three locations, and there was no difference between the 3-year and 5-year survival rate between the patients operated on for gastric cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / complications. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardia. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594065.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


56. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


57. Ohdaira H, Noro T, Terada H, Kameyama J, Ohara T, Yoshino K, Kitajima M, Suzuki Y: New double-stapling technique for esophagojejunostomy and esophagogastrostomy in gastric cancer surgery, using a peroral intraluminal approach with a digital stapling system. Gastric Cancer; 2009;12(2):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New double-stapling technique for esophagojejunostomy and esophagogastrostomy in gastric cancer surgery, using a peroral intraluminal approach with a digital stapling system.
  • In the abdominal-transhiatal approach for resection of adenocarcinoma of the cardia or subcardia, and in laparoscopy-assisted total gastrectomy (LATG), the use of a circular stapling device has potential problems with the placement of the purse-string suture and insertion of the anvil of the instrument.
  • [MeSH-major] Digestive System Surgical Procedures / instrumentation. Digestive System Surgical Procedures / methods. Stomach Neoplasms / surgery. Surgical Stapling / instrumentation. Surgical Stapling / methods
  • [MeSH-minor] Anastomosis, Surgical / instrumentation. Anastomosis, Surgical / methods. Esophagus / surgery. Humans. Stomach / surgery. Surgical Staplers. Sutures

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2001;4(2):98-102 [11706768.001]
  • [Cites] Surg Clin North Am. 1989 Dec;69(6):1227-36 [2512659.001]
  • [Cites] Gastric Cancer. 2007;10(3):176-80 [17922096.001]
  • [Cites] Surg Technol Int. 2005;14:113-7 [16525962.001]
  • [Cites] Obes Surg. 2003 Dec;13(6):837-41 [14738666.001]
  • [Cites] Gastric Cancer. 2007;10(3):181-6 [17922097.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):50-2 [2405935.001]
  • [Cites] Gastric Cancer. 1999 Dec;2(4):230-234 [11957104.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):127-9 [9354169.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Aug;14(4):230-3 [15472555.001]
  • [Cites] Am J Surg. 2002 Jul;184(1):58-60 [12135722.001]
  • [Cites] Am J Surg. 1997 Jul;174(1):61-2 [9240954.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):174-6 [11574091.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1166-74 [16055298.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):909-12 [2804585.001]
  • [Cites] Obes Surg. 2003 Feb;13(1):88-94 [12630620.001]
  • (PMID = 19562464.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Rubenstein JH, Davis J, Marrero JA, Inadomi JM: Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther; 2005 Aug 1;22(3):267-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia.
  • BACKGROUND: Obesity is a risk factor for adenocarcinomas of the oesophagus and gastric cardia.
  • AIM: To estimate the risk of diabetes mellitus on the development of adenocarcinoma of distal oesophagus and gastric cardia beyond that of gastro-oesophageal reflux disease.
  • CONCLUSIONS: Within the limitations of this case-control study, there is no evidence of an association between diabetes and adenocarcinoma of the oesophagus or gastric cardia among US veterans with gastro-oesophageal reflux disease.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Diabetes Mellitus. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091065.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA864000; United States / NIDDK NIH HHS / DK / DK064909
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


59. Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, Park DJ, Lee HS, Jung HC, Song IS: Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol; 2010 Mar;25(3):512-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography.
  • BACKGROUND AND AIM: The aim of this study was to determine the accuracy of endoscopic ultrasonography (EUS) and multidetector-row computed tomography (MDCT) for the locoregional staging of gastric cancer.
  • EUS and computed tomography (CT) are valuable tools for the preoperative evaluation of gastric cancer.
  • The performance of EUS and MDCT for large lesions and lesions at the cardia and angle had significantly lower accuracy than that of other groups.
  • For EUS, the early gastric cancer lesions with ulcerative changes had significantly lower accuracy than those without ulcerative changes.
  • CONCLUSIONS: For the preoperative assessment of individual T and N staging in patients with gastric cancer, the accuracy of MDCT was close to that of EUS.
  • Both EUS and MDCT are useful complementary modalities for the locoregional staging of gastric cancer.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370729.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


60. Wilkinson NW, Howe J, Gay G, Patel-Parekh L, Scott-Conner C, Donohue J: Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation. Ann Surg Oncol; 2008 Jun;15(6):1644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation.
  • BACKGROUND: While the overall incidence of gastric cancer has declined in the United States of America, the incidence of proximal gastric cancers has increased.
  • The purpose of this analysis was to highlight key differences between proximal and distal gastric cancer as they relate to presentation and treatment.
  • METHODS: Data on 6,099 patients diagnosed with gastric adenocarcinoma were collected as a patient care evaluation under the auspices of the American College of Surgeons Commission on Cancer.
  • RESULTS: The proximal cancer group included 1,924 patients (87% cardia, 13% fundus) and the distal cancer group included 1,311 patients (85% antrum, 15% pylorus).
  • Proportionately, proximal cancer cases were male (P < 0.01), younger (P < 0.01), and White (P < 0.01); whereas, distal gastric cancer cases were Black (P < 0.01), Hispanic (P < 0.01), and Asian (P = 0.01).
  • CONCLUSIONS: The populations that developed proximal verses distal gastric cancer differed with respect to sex, age, and racial background.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392661.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Lagergren J, Jansson C, Viklund P: Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study. Eur J Cancer; 2006 Sep;42(14):2359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study.
  • The aim of this study was to test the hypothesis that chewing gum is associated with risk of oesophageal and cardia adenocarcinoma.
  • In all, 189 and 262 patients with oesophageal and cardia adenocarcinoma, respectively, and 820 population-based control subjects were interviewed.
  • Regular users of chewing gum (P3 times/week for P6 months) were not at increased risk of oesophageal adenocarcinoma (OR 1.0, 95% CI 0.6-2.2), and no duration-response relation was observed (P = 0.38).
  • No association between regular gum chewing and cardia adenocarcinoma was found (OR 1.0, 95% CI 0.6-1.7), irrespective of duration of use (P = 0.56).
  • In conclusion, with regard to risk of oesophageal or cardia adenocarcinoma, gum chewing seems harmless.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Chewing Gum / adverse effects. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890425.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chewing Gum
  •  go-up   go-down


62. Tepes B: Can gastric cancer be prevented? J Physiol Pharmacol; 2009 Dec;60 Suppl 7:71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can gastric cancer be prevented?
  • Gastric adenocarcinoma is the fourth most common malignancy worldwide and is globally the second leading cause of cancer-related deaths each year.
  • Among the risk factors are genetic factors (genetic diffuse gastric cancer - E-cadherin mutation (CDH1), pro- and anti-inflammatory cytokine genes and innate immune response gene polymorphisms), environmental factors (infection with the bacterium Helicobacter pylori (H. pylori), Epstein-Barr virus, nutrition: nitroso compounds, salt and antioxidants intake) and other factors (pernicious anemia, gastric polyps, gastric surgery, reproductive hormones, smoking).
  • The bacterium H. pylori has been found to be the major carcinogen in gastric cancer development.
  • Approximately 65%-80% of non-cardia gastric adenocarcinoma is attributable to H. pylori infection.
  • One percent of patients infected with H. pylori will develop gastric cancer.
  • American and European guidelines on the management of H. pylori infection recommend H. pylori eradication in all patients with atrophy and/or intestinal metaplasia and in all first-degree relatives of gastric cancer patients.
  • In the Asian Pacific Gastric Cancer Consensus, it was suggested for the first time that it is time for population-based screening and treatment of H. pylori infection in regions with gastric cancer incidence above 20/100000 per year.
  • Population screen and treat of H. pylori infection should be recommended in regions with gastric cancer incidence above 20/100000 per year.
  • This can be a good approach in H. pylori infected patients before they develop premalignant gastric lesions.
  • [MeSH-major] Adenocarcinoma / prevention & control. Stomach Neoplasms / prevention & control
  • [MeSH-minor] Animals. Early Detection of Cancer. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / physiopathology. Helicobacter pylori. Humans. Mass Screening. Patient Education as Topic. Risk Factors. Stomach Diseases / physiopathology. Stomach Diseases / prevention & control. Stomach Diseases / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388948.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 74
  •  go-up   go-down


63. Lundell LR: Etiology and risk factors for esophageal carcinoma. Dig Dis; 2010;28(4-5):641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trends toward increasing incidence rates were observed for esophageal and gastric cardia adenocarcinoma in Western countries and were associated with trends toward stabilizing or declining incidence rates for esophageal squamous cell carcinoma, suggesting that these tumors might be associated with distinct risk factors.
  • Overweight and obesity have been consistently related to esophageal adenocarcinoma, but not to squamous cell carcinoma.
  • The influence of obesity on esophageal adenocarcinoma and gastric cardia adenocarcinoma may be related to higher incidence of gastroesophageal reflux in obese persons since the risk of gastroesophageal reflux is strongly related to the risk for Barrett's esophagus.
  • Tobacco smoking is a strong risk factor for esophageal squamous cell carcinoma, but is only a weak risk factor for esophageal adenocarcinoma.
  • Alcohol consumption is a strong risk factor for esophageal squamous cell carcinoma, but is not consistently related to esophageal adenocarcinoma.
  • It has been suggested that infection with H. pylori is protective to adenocarcinoma, but might be a risk factor for squamous cell carcinoma, although the role of H. pylori in the etiology of these cancers remains somewhat unclear.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088416.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


64. Jeon J, Luebeck EG, Moolgavkar SH: Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control; 2006 Sep;17(7):971-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States).
  • A number of hypotheses have been advanced to explain the rapid increase of the incidence of esophageal adenocarcinoma in the US.
  • To address this problem, we have developed multi-stage carcinogenesis models that describe the age-specific incidence of adenocarcinoma of the esophagus and of the gastric cardia with separate adjustments for temporal trends.
  • We fit these models separately to the incidence of adenocarcinoma of the esophagus and of the gastric cardia reported in the Surveillance Epidemiology and End Results (SEER) registry over the period 1973-2000.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841264.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047658; United States / NCI NIH HHS / CA / R01 CA119224-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Jenab M, Riboli E, Ferrari P, Friesen M, Sabate J, Norat T, Slimani N, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Boeing H, Schulz M, Linseisen J, Nagel G, Trichopoulou A, Naska A, Oikonomou E, Berrino F, Panico S, Palli D, Sacerdote C, Tumino R, Peeters PH, Numans ME, Bueno-de-Mesquita HB, Büchner FL, Lund E, Pera G, Chirlaque MD, Sánchez MJ, Arriola L, Barricarte A, Quirós JR, Johansson I, Johansson A, Berglund G, Bingham S, Khaw KT, Allen N, Key T, Carneiro F, Save V, Del Giudice G, Plebani M, Kaaks R, Gonzalez CA: Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer; 2006 Aug 07;95(3):406-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition.
  • Despite declining incidence rates, gastric cancer (GC) is a major cause of death worldwide.
  • The objective of this study was to determine the association of plasma levels of seven common carotenoids, their total plasma concentration, retinol and alpha- and gamma-tocopherol, with the risk of gastric adenocarcinoma in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), a large cohort involving 10 countries.
  • A secondary objective was to determine the association of total sum of carotenoids, retinol and alpha-tocopherol on GCs by anatomical subsite (cardia/noncardia) and histological subtype (diffuse/intestinal).
  • [MeSH-major] Adenocarcinoma / epidemiology. Carotenoids / administration & dosage. Diet. Stomach Neoplasms / epidemiology. Tocopherols / administration & dosage. Vitamin A / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2087-92 [16172214.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):480-4 [7759153.001]
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):133-40 [10861464.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3479S-3485S [15570057.001]
  • [Cites] Int J Cancer. 1996 Apr 10;66(2):145-50 [8603802.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Mar;13(3):233-7 [11293441.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 May;12(5):497-503 [10833091.001]
  • [Cites] Eur J Clin Nutr. 2005 Dec;59(12):1397-408 [16160701.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1997 Jun 20;694(1):71-81 [9234850.001]
  • [Cites] Cancer. 1993 May 15;71(10):2926-33 [8490820.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Clin Chem. 1989 Dec;35(12):2313-6 [2591049.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):737-48 [10679641.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1145-9 [8602179.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):896-901 [2335393.001]
  • [Cites] Cancer Causes Control. 2003 Sep;14(7):645-55 [14575362.001]
  • [Cites] Nutr Cancer. 1999;34(1):56-61 [10453442.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1772-80 [15533906.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7501-4 [2253198.001]
  • [Cites] Am J Clin Nutr. 1983 Oct;38(4):631-9 [6624705.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):638-44 [8194870.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1414-6 [13130117.001]
  • [Cites] Cancer Res. 1983 Jul;43(7):3034-40 [6189589.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] N Engl J Med. 1984 Feb 16;310(7):430-4 [6537988.001]
  • [Cites] Int J Epidemiol. 1997;26 Suppl 1:S6-14 [9126529.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:73-82 [9701005.001]
  • [Cites] Nutr J. 2004 Oct 20;3:19 [15496224.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8 [11106679.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1941s-1943s [8137316.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1424S-1426S [7495242.001]
  • [Cites] Am J Epidemiol. 1994 Mar 1;139(5):466-73 [8154470.001]
  • [Cites] Dig Liver Dis. 2002 Sep;34 Suppl 2:S72-7 [12408446.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):585-90 [10521790.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):195-202 [9103291.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1021-8 [9305701.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):559S-569S [12936950.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):369-74 [2040530.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):811-4 [8896892.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] Am J Epidemiol. 1991 Apr 15;133(8):766-75 [2021143.001]
  • [Cites] Am J Epidemiol. 1995 Nov 1;142(9):955-60 [7572976.001]
  • [Cites] Eur J Clin Nutr. 2005 Dec;59(12):1387-96 [16160702.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1607-12 [11018097.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):71-5 [10334645.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1338-44 [16174855.001]
  • [Cites] Scand J Gastroenterol. 1998 Mar;33(3):294-300 [9548624.001]
  • [Cites] Jpn J Cancer Res. 1995 Oct;86(10):916-23 [7493909.001]
  • [Cites] Cancer Causes Control. 1991 Jul;2(4):227-33 [1873452.001]
  • (PMID = 16832408.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527; United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11103-57-4 / Vitamin A; 1406-66-2 / Tocopherols; 36-88-4 / Carotenoids
  • [Other-IDs] NLM/ PMC2360629
  •  go-up   go-down


66. Wen S, Moss SF: Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett; 2009 Sep 8;282(1):1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori virulence factors in gastric carcinogenesis.
  • Helicobacter pylori infection is the most important risk factor in the development of non-cardia gastric adenocarcinoma; host genetic variability and dietary co-factors also modulate risk.
  • Improved understanding of the pathogenesis of H. pylori-associated gastric cancer may improve risk stratification for prevention and therapy.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 May 24;26(24):3462-72 [17160020.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Microbiology. 2007 Sep;153(Pt 9):2896-909 [17768234.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5433-40 [17911630.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):862-6 [17943123.001]
  • [Cites] J Cell Physiol. 2008 Mar;214(3):582-7 [17786942.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Cell Host Microbe. 2008 Jan 17;3(1):20-9 [18191791.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):379-87 [18199531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1003-8 [18192401.001]
  • [Cites] Cell Microbiol. 2008 Mar;10(3):781-94 [18005242.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):510-4 [18341483.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1267; author reply 1268 [18395110.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(4):971-80 [11929545.001]
  • [Cites] Science. 2002 Jul 26;297(5581):573-8 [12142529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] Cell Microbiol. 2003 Jan;5(1):25-40 [12542468.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):951-7 [12615708.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Science. 2003 May 30;300(5624):1430-4 [12775840.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1099-102 [12934009.001]
  • [Cites] Cell Microbiol. 2004 Feb;6(2):167-74 [14706102.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2106-11 [14762173.001]
  • [Cites] J Infect Dis. 2004 Mar 1;189(5):820-7 [14976598.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7727-32 [15128946.001]
  • [Cites] Science. 2004 Jul 23;305(5683):519-22 [15273394.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1166-74 [15489856.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10570-5 [1587837.001]
  • [Cites] Science. 1993 Dec 17;262(5141):1892-5 [8018146.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] Trends Microbiol. 1994 Jul;2(7):221-8 [8081648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9720-4 [7937879.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] J Clin Pathol. 1995 Oct;48(10):967-9 [8537502.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):242-9 [8657240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14648-53 [8962108.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):92-9 [8978347.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1344-7 [9163441.001]
  • [Cites] Nature. 1997 Aug 7;388(6642):539-47 [9252185.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):135-40 [9419220.001]
  • [Cites] Science. 1998 Jan 16;279(5349):373-7 [9430586.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2258-63 [9666002.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10212-7 [9707626.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):813-20 [9710450.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):176-80 [9923682.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):259-68 [9922305.001]
  • [Cites] Science. 1999 May 21;284(5418):1328-33 [10334982.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16923-8 [15557006.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):320-32 [15759043.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):15390-7 [15689619.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):833-48 [15825067.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):23130-7 [15831497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9300-5 [15972330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9661-6 [15980153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Nov;21(6):653-9 [16220040.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 [16258069.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Infect Immun. 2006 Jan;74(1):273-81 [16368981.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1181-90 [16618412.001]
  • [Cites] Infect Immun. 2006 Jul;74(7):4375-8 [16790815.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):633-49 [16997150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1920-8 [17035400.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e110 [17121461.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):915-8 [17287725.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1309-19 [17408661.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):115-28 [10620610.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Infect Immun. 2000 Jun;68(6):3754-7 [10816542.001]
  • [Cites] Int J Cancer. 2000 Aug 1;87(3):322-7 [10897035.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1601-10 [11104802.001]
  • [Cites] J Clin Invest. 2001 Mar;107(5):611-20 [11238562.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1903-9 [11280745.001]
  • [Cites] J Clin Microbiol. 2001 Jul;39(7):2463-5 [11427555.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):823-9 [11606496.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6499-508 [11673417.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):3033-41 [11884476.001]
  • [Cites] Mol Microbiol. 2001 Dec;42(5):1337-48 [11886563.001]
  • (PMID = 19111390.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125126-01A1; United States / NCI NIH HHS / CA / R21 CA125126-01A1; United States / NCI NIH HHS / CA / R01 CA111533-03; United States / NCI NIH HHS / CA / R21 CA125126; United States / NCI NIH HHS / CA / CA111533-03; United States / NCI NIH HHS / CA / R01 CA111533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori; 0 / Virulence Factors; 0 / cagA protein, Helicobacter pylori
  • [Number-of-references] 96
  • [Other-IDs] NLM/ NIHMS133225; NLM/ PMC2746929
  •  go-up   go-down


67. González CA, Pera G, Agudo A, Bueno-de-Mesquita HB, Ceroti M, Boeing H, Schulz M, Del Giudice G, Plebani M, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Allen N, Key TJ, Bingham S, Day NE, Linseisen J, Nagel G, Overvad K, Jensen MK, Olsen A, Tjønneland A, Büchner FL, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Roukos D, Trichopoulou A, Psaltopoulou T, Lund E, Casagrande C, Slimani N, Jenab M, Riboli E: Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer; 2006 May 15;118(10):2559-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).
  • It is considered that fruit and vegetable (F&V) protect against oesophagus and gastric cancer (GC).
  • No evidence exists from cohort studies about adenocarcinoma of oesophagus (ACO).
  • We found a negative but non significant association between citrus fruit intake and the cardia site (calibrated HR 0.77; 95% CI 0.47-1.22 per 100 g increase) while no association was observed with the non-cardia site.
  • Citrus fruit consumption may have a role in the protection against cardia GC and ACO.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Fruit. Stomach Neoplasms / prevention & control. Vegetables

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • [CommentIn] Int J Cancer. 2006 Dec 15;119(12):2991; author reply 2992 [17016826.001]
  • (PMID = 16380980.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Ge H, Wang YM, Cao YY, Zhang XF, Li Y, Guo W, Wang N, Zhang JH: [Correlation of p73 polymorphisms to genetic susceptibilities to esophageal carcinoma and gastric cardiac carcinoma]. Ai Zheng; 2006 Nov;25(11):1351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of p73 polymorphisms to genetic susceptibilities to esophageal carcinoma and gastric cardiac carcinoma].
  • This study was to investigate the correlation of p73 G4C14-A4T14 polymorphisms to susceptibilities to esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in a high incidence region of Hebei Province.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Nuclear Proteins / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Cardia. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Smoking

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094900.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


69. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia]. Chin J Cancer; 2010 Jan;29(1):94-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia].
  • BACKGROUND AND OBJECTIVE: The incidence of adenocarcinoma of the cardia has recently increased.
  • This study compared the clinicopathology and prognosis of patients with gastric cardia adenocarcinoma in different periods between 1984 and 2003.
  • METHODS: A total of 589 patients with pathologically confirmed gastric cardia adenocarcinoma hospitalized in Sun Yat-sen University Cancer Center between 1984 and 2003 were divided into 5-year groups.
  • CONCLUSIONS: During the past 20 years, associated with the upward-trending incidence of gastric cardia adenocarcinoma, the admission rate at our hospital of patients with the tumor increased.
  • [MeSH-major] Adenocarcinoma. Cardia / pathology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038318.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer; 2007;10(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
  • BACKGROUND: MK-1, the target molecule of FU-MK-1, is encoded by the GA733-2 gene, which is currently being used as a target in clinical trials for gastric, intestinal and biliary cancer treatment with monoclonal antibodies.
  • METHODS: The expression of p53 protein and MK-1 antigen was investigated in specimens from 42 patients with gastric carcinoma.
  • MK-1 expression was more frequent in cardia tumors (71%), in large (>3 cm) tumors (60%-64%), and in specimens from patients with more than five metastatic lymph nodes (69%).
  • Of these 20 patients, 15 (52%) had tubular adenocarcinoma (TA) and 5 (38%) had signet ring cell carcinoma. p53 expression was more frequent in the tumors of male patients (55% vs 27%); in poorly differentiated TAs (60% vs 47% in well-to-moderately differentiated TAs); in smaller tumors (< or = 3 cm, 72% vs 43%-50% in larger tumors); in patients with a prominent inflammatory response (61% vs 21%; P < 0.02); and in patients with lymphatic vessel invasion (77% vs 34%; P < 0.02).
  • Most patients with p53- and MK-1-positive gastric carcinomas and those more than five metastatic lymph nodes had a poor prognosis.
  • CONCLUSION: The study found that the expression of both p53 and MK-1 was frequent in aggressive gastric carcinomas; however, extensive lymph node involvement (more than five nodes) was the only significant factor related to overall survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(4):343-7 [8205349.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):211-6 [16616808.001]
  • [Cites] Arch Pathol Lab Med. 1977 Nov;101(11):568-71 [334106.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Br J Cancer. 1994 May;69(5):943-6 [8180028.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2649-55 [7538044.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):653-61 [8398688.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):584-9 [8099338.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):231-8 [10761711.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Virchows Arch. 1994;424(2):187-93 [8180781.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):769-76 [12014649.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1247-53 [7977948.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2001-7 [12174877.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3952-6 [6744310.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):174-86 [8424417.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2439-47 [7680948.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2443-50 [1933781.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Histopathology. 2004 Apr;44(4):323-31 [15049897.001]
  • (PMID = 17577621.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


71. Mehta SP, Bailey D, Davies N: Comparative outcome of oesophagogastric cancer in younger patients. Ann R Coll Surg Engl; 2010 Sep;92(6):515-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The incidence of oesophageal and gastric cardia adenocarcinoma has increased rapidly over the previous two decades.
  • PATIENTS AND METHODS: Every patient diagnosed with oesophageal, junctional or gastric cancer under the age of 55 years and every subsequent patient over the age of 55 years was accepted into this study.
  • Patients under the age of 55 years diagnosed with oesophageal or gastric cancer appear to have a better prognosis than those aged over 55 years.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2005-12 [11467625.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):600-3 [11922553.001]
  • [Cites] Gut. 2002 Aug;51(2):296-7 [12117899.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):417-20 [1558797.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2425-9 [7922995.001]
  • [Cites] Gut. 1997 Oct;41(4):513-7 [9391251.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Am Surg. 2004 Nov;70(11):954-8 [15586504.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):784-91 [15784019.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1725-8 [17024539.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):17-22 [17190757.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):957-65 [17313501.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):75-9 [9934734.001]
  • (PMID = 20522292.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3182797
  •  go-up   go-down


72. Yu JX, Ren YB, Fu B, Zhao Q, Zhang XD: [Changing trends in the clinicopathological characteristics of patients with gastric carcinoma undergoing surgery between 1979 and 2008 in Liaocheng Shandong province]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Sep;13(9):668-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing trends in the clinicopathological characteristics of patients with gastric carcinoma undergoing surgery between 1979 and 2008 in Liaocheng Shandong province].
  • OBJECTIVE: To evaluate the changing trends in clinicopathological characteristics of patients with gastric carcinoma undergoing surgery between 1979 and 2008.
  • METHODS: Two thousand seven hundred and fifteen patients with gastric cancer who received operation in Liaocheng People's hospital between 1979 and 2008 were analyzed retrospectively, and were compared to 168 patients between 1974 and 1978.
  • Comparing the tumor distribution of gastric cancer during 1979-2008 with that during 1974-1978, proportion of gastric cardia and fundus cancer was higher (45.7% vs. 13.0%, χ2=56.596, P<0.01), while the proportion of gastric antrum cancer was lower (44.9% vs. 73.2%, χ2=53.980, P<0.01).
  • There was no significant difference in gastric body cancer (13.8% vs. 9.4%, χ2=2.026, P=0.155).
  • Time series analysis showed the patient age during 1979 to 2008 increased (Root mean square error=1.275, R-square=0.702), gastric cardia and fundus cancer was increasing and antrum cancer was decreasing (Root mean square error=0.055, R-square=0.798).
  • CONCLUSIONS: In the past 30 years from 1979 to 2008, the male to female ratio and the median age of surgical patients with gastric cancer increased with time.
  • The gastric cardia and fundus cancer increased over time, however antrum cancer decreased with time.
  • In the past 15 years from 1994 to 2008, the proportion of poorly differentiated adenocarcinoma increased, and that of tubular adenocarcinoma declined.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878573.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


73. Kawasaki H, Kitayama J, Ishigami H, Hidemura A, Kaisaki S, Nagawa H: Solitary splenic metastasis from early gastric cancer: report of a case. Surg Today; 2010;40(1):60-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic metastasis from early gastric cancer: report of a case.
  • We herein describe a case of splenic metastasis from early gastric cancer.
  • A 76-year-old man underwent an endoscopic mucosal resection (EMR) for early gastric carcinoma in the cardia.
  • The lesion was pathologically diagnosed as metastasis from the previous gastric carcinoma, and the patient remains healthy to date without recurrence, more than 2 years after the splenectomy.
  • When solitary metastasis to the spleen is suspected during the postoperative follow-up of a patient with gastric cancer, a splenectomy is a potentially effective treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Splenectomy. Splenic Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / blood. Gastrectomy. Gastric Mucosa / surgery. Gastroscopy. Humans. Lymph Node Excision. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Microbiol Scand A. 1974 Jul;82(4):499-506 [4854372.001]
  • [Cites] Gastric Cancer. 2006;9(4):262-70 [17235627.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):187-91 [9700579.001]
  • [Cites] Pathol Res Pract. 2006;202(5):351-6 [16488085.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3174-8 [8242540.001]
  • [Cites] Surg Today. 2002;32(12):1081-4 [12541027.001]
  • [Cites] Digestion. 2008;77 Suppl 1:23-8 [18204258.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):209-14 [12865463.001]
  • [Cites] Eur J Cancer Clin Oncol. 1981 Dec;17(12):1301-6 [7200031.001]
  • [Cites] Am J Clin Oncol. 2000 Dec;23(6):579-80 [11202800.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):526-30 [10747308.001]
  • [Cites] J Pathol Bacteriol. 1965 Oct;90(2):515-21 [5849609.001]
  • [Cites] Surgery. 1990 May;107(5):489-95 [2333591.001]
  • [Cites] Abdom Imaging. 1995 Jul-Aug;20(4):312-4 [7549732.001]
  • [Cites] Surg Today. 2008;38(12):1144-7 [19039644.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):693-700 [17905010.001]
  • (PMID = 20037842.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


74. Buchs NC, Bucher P, Pugin F, Hagen ME, Morel P: Robot-assisted oncologic resection for large gastric gastrointestinal stromal tumor: a preliminary case series. J Laparoendosc Adv Surg Tech A; 2010 Jun;20(5):411-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted oncologic resection for large gastric gastrointestinal stromal tumor: a preliminary case series.
  • BACKGROUND: Laparoscopic resection of gastric gastrointestinal stromal tumor (GIST) has been shown as feasible and safe in terms of oncologic results.
  • The robotic approach may, by its characteristics, enable the surgeon to perform atypical gastrectomies in an unfavorable location (i.e., close to pylorus or cardia).
  • Its use in oncologic gastric surgery has been poorly defined and has never been reported for GIST.
  • MATERIALS AND METHODS: All patients who underwent robotic-assisted gastric resection for GIST at a single institution from 2006 to 2009 were prospectively followed-up.
  • One patient had a conversion to open surgery because of a suspicion of diffuse adenocarcinoma on fresh frozen section and necessitated a total gastrectomy with a radical lymph node dissection.
  • CONCLUSIONS: The da Vinci robot (Intuitive Surgical, Inc., Sunnyvale, CA) is a valuable instrument for oncologically safe resection with esogastric or duodenogastric junction preservation for an unfavorably located gastric GIST.
  • Moreover, the three-dimensional, high-definition vision, instrument mobility, and ease of performing a difficult suturing enable a safe, large atypical gastrectomy, close to the pylorus or cardia.
  • [MeSH-major] Gastrectomy / instrumentation. Gastrointestinal Stromal Tumors / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459328.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS: Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol; 2009 Mar;24(3):354-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis.
  • There is conflicting data regarding the clinicopathological significance of the risk factors associated with Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC).
  • EBVaGC developed most often in the cardia and body, and it generally showed the diffuse histological type.
  • The clinicopathological and molecular characteristics of EBVaGC are quite different from those of conventional gastric adenocarcinoma.
  • [MeSH-major] Carcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335785.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 75
  •  go-up   go-down


76. Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, Tsujii S, Onishi S, Kobayashi M, Hanazaki K: Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg; 2008 Feb;206(2):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach?
  • BACKGROUND: Although the incidence of gastric cardia cancer is considerably less than more distal gastric cancer, the rate of occurrence is now increasing.
  • The objective of this study was to evaluate and compare the clinicopathologic findings of gastric cardia and more distal stomach adenocarcinoma.
  • STUDY DESIGN: Patients included in our study were those who underwent operations for gastric adenocarcinoma in our institute from 1981 to 2006, and who had undergone complete medical history, including history of daily alcohol consumption; smoking; body mass index; and pathologic examinations.
  • A total of 843 patients were included in our study, and were divided into cardia and noncardia cancer groups.
  • RESULTS: Among the 843 patients, 23 (2.8%) had gastric cardia cancer.
  • Mean size of cardia tumors was larger than noncardia tumors.
  • Although noncardia cancer was often detected at an early stage, gastric cardia cancer was most often diagnosed at an advanced stage.
  • Pathologically, cardia cancer was more invasive and had more lymphatic permeation and lymph node metastasis than noncardia cancer.
  • CONCLUSIONS: Gastric cardia cancer occurs at a low incidence of only 2.8% of resected gastric cancers.
  • Unlike cases of gastric cardia cancer in Western populations, body mass index is not associated with occurrence of gastric cardia cancer in our study.
  • Because gastric cardia cancer appears more aggressive than noncardia gastric cancer, early diagnosis and intervention are important.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222384.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Mesenas S, Vu C, McStay M, Forshaw M, Doig L, Mason R, Boyle N, Meenan J: A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy. Dis Esophagus; 2008;21(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy.
  • The true value of endoscopic ultrasound (EUS) post-neoadjuvant chemotherapy for esophageal carcinoma is not established.
  • Superior loco-regional detail may yield useful staging and prognostic information but information on its accuracy, as compared with computed tomography (CT), remains undefined and limited by small study size.
  • We prospectively studied 109 patients with gastroesophageal cancer; 99 of whom were undergoing surgery.
  • All had EUS and helical CT imaging before and after neoadjuvant chemotherapy and the results were compared with pathological staging of resected specimens.
  • Tumor response was assessed by the reduction in maximal tumor depth at EUS and correlated with patient survival.
  • There was no difference in T and N stage accuracies between EUS and CT following neoadjuvant chemotherapy. manova showed a reduction in maximal tumor depth by > 50% at EUS to be associated with longer survival (relative risk = 0.48, P < 0.05).
  • EUS responders had a median survival of 38 months compared to 30 months for non-responders (P < 0.05).
  • The identification of lymphadenopathy at radial EUS was not predictive of survival.
  • This large series study demonstrates the staging accuracy of CT and non-biopsy EUS in the setting of neoadjuvant chemotherapy for gastroesophageal cancer to be equivalent and poor.
  • An endosonography may contribute useful clinical information in respect of potential survival.
  • It is questionable whether radial EUS should be included in protocols for restaging.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197937.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Früh M, Ruhstaller T, Neuweiler J, Cerny T: Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie; 2005 Jan;28(1):38-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation.
  • BACKGROUND: Skin metastases from gastric cancer are rare and generally occur at a very late stage in the course of the disease.
  • CASE REPORT: A 60-year-old patient with localized adenocarcinoma of the cardia (stage II) was primarily treated with extended total gastrectomy with transhiatal resection of the distal esophagus.
  • CONCLUSION: We report a long-term disease-free survival of a patient with isolated cutaneous metastases of a gastric cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Skin Neoplasms / secondary. Skin Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604627.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


79. Wu IC, Wu DC, Yu FJ, Wang JY, Kuo CH, Yang SF, Wang CL, Wu MT: Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol; 2009 Nov 21;15(43):5465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection.
  • RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups.
  • CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Carcinoma, Squamous Cell / microbiology. Cardia / microbiology. Esophageal Neoplasms / microbiology. Helicobacter Infections / blood. Helicobacter Infections / complications. Helicobacter pylori / immunology. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2008 Oct;38(10):760-5 [18837801.001]
  • [Cites] Gut. 2008 Jun;57(6):727-33 [17895354.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):226-33 [11158192.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):658-60 [11531247.001]
  • [Cites] J Gastroenterol. 2002;37 Suppl 13:28-33 [12109662.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):68-76 [12559187.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):123-8 [12593607.001]
  • [Cites] J Periodontol. 2003 Jan;74(1):129-34 [12593608.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1202-4 [14520446.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;212:13-8 [8578226.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1442-7 [9136820.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1316-21 [9260797.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1271-6 [9707050.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):621-4 [10428200.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i1-5 [15711002.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):588-93 [15743356.001]
  • [Cites] Helicobacter. 2005 Aug;10(4):312-7 [16104947.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1999-2000 [16708392.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2827-31 [17036331.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1188-99 [17383866.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):933-40 [17613922.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • (PMID = 19916178.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2778104
  •  go-up   go-down


80. Randjelovic T, Filipovic B, Babic D, Cemerikic V, Filipovic B: Carcinosarcoma of the stomach: a case report and review of the literature. World J Gastroenterol; 2007 Nov 7;13(41):5533-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the stomach: a case report and review of the literature.
  • We report the case of a 62-year-old man with gastric carcinosarcoma, along with its clinical, macroscopic and histopathological features.
  • Macroscopically, a specimen of deformed stomach was obtained that measured 200 mm x 150 mm x 100 mm.
  • A 150 mm x 100 mm x 50 mm exophytic tumoral mass (Borrmann type I) was found, which involved the posterior wall from the cardia to the antrum.
  • Histopathologically, a mixed type of malignancy was revealed: an adenocarcinoma with intestinal metaplasia, with interposed fascicles of fusiform atypical cells and numerous large, rounded and oval cells.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinosarcoma / secondary. Liver Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907304.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Chromogranin A; 0 / KRT18 protein, human; 0 / Keratin-18; 0 / Mucin-1; 0 / Vimentin
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC4171295
  •  go-up   go-down


81. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ: Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep; 2010 Jan;37(1):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China.
  • The aim of the present study was to investigate the association of single nucleotide polymorphisms (SNPs) in matrix metalloproteinase (MMPs) with the risk of gastric cardia adenocarcinoma (GCA) and esophageal squamous cell carcinoma (ESCC).
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinases / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / epidemiology. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. China / epidemiology. Female. Gene Frequency / genetics. Haplotypes / genetics. Humans. Incidence. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1117-21 [15731163.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7549-58 [11114309.001]
  • [Cites] Matrix Biol. 2002 Oct;21(6):487-98 [12392760.001]
  • [Cites] Circ Res. 2000 May 12;86(9):998-1003 [10807873.001]
  • [Cites] Br Heart J. 1995 Mar;73(3):209-15 [7727178.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] Lung Cancer. 2007 May;56(2):273-80 [17208328.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7622-8 [15492291.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2519-24 [15319302.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2614-20 [17473191.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1834-9 [11701474.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3820-3 [12473595.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1024-9 [16311244.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):197-204 [15609121.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gynecol Obstet Invest. 2008;65(1):68-72 [17851253.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2385-9 [15832405.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):405-9 [15250832.001]
  • [Cites] FEBS Lett. 1996 Feb 12;380(1-2):17-20 [8603731.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1748-53 [15930031.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3987-90 [12873995.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):415-33 [11170864.001]
  • [Cites] Biochem Genet. 2008 Apr;46(3-4):137-44 [18210196.001]
  • (PMID = 19562509.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


82. Selinger CP, Ellul P, Smith PA, Cole NC: Oesophageal stent insertion for palliation of dysphagia in a District General Hospital: experience from a case series of 137 patients. QJM; 2008 Jul;101(7):545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endoscopic oesophageal stent insertion is a widely used procedure to alleviate dysphagia caused by malignant strictures of the oesophagus and gastric cardia.
  • RESULTS: Of the 137 patients studied, oesophageal adenocarcinoma was present in 57% of patients, squamous cell oesophageal carcinoma in 37% and gastric adenocarcinoma in 6%.
  • [MeSH-major] Deglutition Disorders / therapy. Esophageal Neoplasms / surgery. Palliative Care / methods. Stents. Stomach Neoplasms / surgery


83. Dietz J, Chaves-E-Silva S, Meurer L, Sekine S, de Souza AR, Meine GC: Short segment Barrett's esophagus and distal gastric intestinal metaplasia. Arq Gastroenterol; 2006 Apr-Jun;43(2):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short segment Barrett's esophagus and distal gastric intestinal metaplasia.
  • Barrett's esophagus is a risk factor to develop adenocarcinoma of the esophagus.
  • While Barrett's esophagus develops as a result of chronic gastroesophageal reflux disease, intestinal metaplasia in the gastric cardia is a consequence of chronic Helicobacter pylori infection and is associated with distal gastric intestinal metaplasia.
  • It can be difficult to determine whether short-segment columnar epithelium with intestinal metaplasia are lining the esophagus (a condition called short segment Barrett's esophagus) or the proximal stomach (a condition called intestinal metaplasia of the gastric cardia).
  • AIMS: To study the association of short segment Barrett's esophagus (length <3 cm) with gastric intestinal metaplasia (antrum or body) and infection by H. pylori.
  • Biopsies were obtained immediately below the squamous-columnar lining, from gastric antrum and gastric corpus for investigation of intestinal metaplasia and H. pylori.
  • Gastric intestinal metaplasia (antrum or body) was diagnosed in 21 from 42 (50.0%) patients in the group with esophageal intestinal metaplasia and 7 from 47 (14.9%) patients in the group with esophageal columnar appearing mucosa but without intestinal metaplasia.
  • In the present study, short segment intestinal metaplasia in the esophagus is associated with distal gastric intestinal metaplasia.
  • [MeSH-major] Barrett Esophagus / pathology. Gastroesophageal Reflux / pathology. Helicobacter Infections / pathology. Intestines / pathology. Stomach / pathology
  • [MeSH-minor] Biopsy. Cardia / pathology. Esophagoscopy. Female. Gastritis / microbiology. Gastritis / pathology. Humans. Male. Metaplasia / pathology. Middle Aged


84. Rutegård M, Shore R, Lu Y, Lagergren P, Lindblad M: Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer; 2010 Apr;46(6):1093-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006.
  • BACKGROUND: Oesophageal and gastric adenocarcinoma share a male predominance not seen for other adenocarcinomas of the gastrointestinal tract.
  • METHODS: The Swedish Cancer Register was used to collect primary oesophageal, gastric cardia, non-cardia gastric, colonic and pancreatic adenocarcinoma cases aged 25-84, during the study period of 1970-2006.
  • RESULTS: The sex ratio for oesophageal adenocarcinoma ranged from approximately 10:1 to 4:1, presenting a seemingly consistent decline with age.
  • The sex ratio for non-cardia gastric adenocarcinoma, however, increased with age to reach 2:1 at a point one to two decades after menopause, where the ratio levelled off and eventually declined.
  • There was no discernible time period effect concerning any type of adenocarcinoma.
  • The ratios for gastric cardia, colonic and pancreatic adenocarcinoma were stable with age.
  • CONCLUSION: This study indicates separate patterns of age-dependency of the sex difference in oesophageal and non-cardia gastric adenocarcinoma incidence.
  • The non-cardia gastric adenocarcinoma pattern might be due to a protective effect during premenopausal years for the female population, while the seemingly steady decline in sex ratio in oesophageal adenocarcinoma indicates a mechanism independent of menopause.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology. Esophageal Neoplasms / epidemiology. Pancreatic Neoplasms / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cardia. Female. Humans. Incidence. Male. Middle Aged. Sex Distribution. Sweden / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20188539.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Larsson SC, Giovannucci E, Wolk A: Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology; 2006 Oct;131(4):1271-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis.
  • We conducted a systematic review with meta-analysis of epidemiologic studies evaluating the association of folate intake or genetic polymorphisms in 5,10-methylenetetrahydrofolate reductase (MTHFR), a central enzyme in folate metabolism, with risk of esophageal, gastric, or pancreatic cancer.
  • RESULTS: The summary relative risks for the highest versus the lowest category of dietary folate intake were 0.66 (95% confidence interval [CI], 0.53-0.83) for esophageal squamous cell carcinoma (4 case-control), 0.50 (95% CI, 0.39-0.65) for esophageal adenocarcinoma (3 case-control), and 0.49 (95% CI, 0.35-0.67) for pancreatic cancer (1 case-control, 4 cohort); there was no heterogeneity among studies.
  • Results on dietary folate intake and risk of gastric cancer (9 case-control, 2 cohort) were inconsistent.
  • In most studies, the MTHFR 677TT (variant) genotype, which is associated with reduced enzyme activity, was associated with an increased risk of esophageal squamous cell carcinoma, gastric cardia adenocarcinoma, noncardia gastric cancer, gastric cancer (all subsites), and pancreatic cancer; all but one of 22 odds ratios were >1, of which 13 estimates were statistically significant.
  • CONCLUSIONS: These findings support the hypothesis that folate may play a role in carcinogenesis of the esophagus, stomach, and pancreas.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adenocarcinoma / prevention & control. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / prevention & control. Case-Control Studies. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / genetics. Esophageal Neoplasms / prevention & control. Humans. Pancreatic Neoplasms / epidemiology. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / prevention & control. Polymorphism, Genetic. Risk Factors. Stomach Neoplasms / epidemiology. Stomach Neoplasms / genetics. Stomach Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030196.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


86. Kutup A, Yekebas EF, Izbicki JR: Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:115-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Esophageal and gastric cancers are aggressive neoplasms with a poor prognosis.
  • The potential role and -benefit of an antibody-based treatment as a therapeutic target would be of particular interest in tumors with a notoriously poor prognosis such as esophageal cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676876.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


87. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR: Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst; 2006 Oct 18;98(20):1445-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity.
  • BACKGROUND: Colonization with Helicobacter pylori is a risk factor for gastric adenocarcinoma, but the magnitude of this association and its relationship to anatomic location of the cancer, duration of follow-up, age at diagnosis, histologic subtype, and H. pylori strain differences are less clear.
  • From 1985 to 1999, 243 incident cases of gastric adenocarcinoma were diagnosed in cohort members.
  • Serum samples from 234 case subjects (173 with noncardia gastric cancers and 61 with gastric cardia cancers) and 234 age-matched control subjects were assayed for antibodies against H. pylori whole-cell and CagA antigens.
  • We fit conditional logistic regression models to estimate the unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association of H. pylori seropositivity, defined as seropositivity to either whole-cell or CagA antigens, with noncardia gastric and gastric cardia cancers.
  • RESULTS: H. pylori seropositivity was strongly associated with the risk of noncardia gastric cancer (adjusted OR = 7.9, 95% CI = 3.0 to 20.9) but was inversely associated with the risk of gastric cardia cancer (adjusted OR = 0.31, 95% CI = 0.11 to 0.89). H. pylori seropositivity rates did not vary statistically significantly by length of follow-up, age at diagnosis, or histologic subtype.
  • A calculation of rates showed that the absolute risks of noncardia gastric and cardia gastric adenocarcinomas in the H. pylori-positive participants of this cohort would be 63 and 12 per 100,000 person-years, respectively, whereas corresponding rates in H. pylori-negative participants would be 8 and 37 per 100,000 person-years, respectively.
  • CONCLUSION: H. pylori is a strong risk factor for noncardia gastric cancer but is inversely associated with the risk of gastric cardia cancer.
  • These findings bolster the hypothesis that decreasing H. pylori prevalence during the past century may have contributed to lower rates of noncardia cancer and higher rates of cardia cancer in Western countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / microbiology. Cardia. Helicobacter Infections / complications. Helicobacter Infections / epidemiology. Helicobacter pylori. Stomach Neoplasms / epidemiology. Stomach Neoplasms / microbiology


88. Crane SJ, Richard Locke G 3rd, Harmsen WS, Diehl NN, Zinsmeister AR, Joseph Melton L 3rd, Romero Y, Talley NJ: The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther; 2007 Feb 15;25(4):447-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site.
  • BACKGROUND: The incidence rates of gastric and oesophageal adenocarcinoma are changing significantly, but little is known about specific sub-sites.
  • AIM: To use a population-based approach to describe the trends in the site-specific incidence of oesophageal and gastric adenocarcinoma.
  • METHODS: Using the Rochester Epidemiology Project, all cases of gastric and oesophageal adenocarcinoma among Olmsted County, Minnesota, residents first diagnosed between 1971 and 2000 were identified (n = 186).
  • RESULTS: Between the decades of 1971-1980 and 1991-2000, the incidence of oesophageal adenocarcinoma increased significantly from 0.4 to 2.5 per 100 000 person-years.
  • The incidence of adenocarcinoma of the oesophagogastric junction also increased from a rate of 0.6 to 2.2 per 100 000 person-years.
  • The incidence rate of cancer involving the gastric cardia was stable but the incidence of adenocarcinoma involving distal gastric sites declined.
  • Combined oesophageal and oesophagogastric junction adenocarcinoma (4.7 per 1 000 000 person-years) was as common as gastric adenocarcinoma (3.4 per 100 000 person-years) in 1991-2000.
  • CONCLUSIONS: The incidence rates of adenocarcinoma involving proximal gastric sub-sites do not appear to be increasing in a manner similar to those involving oesophageal sub-sites.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270000.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01AR30582
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


89. Yamamoto J, Ohshima K, Kohno S, Ichimiya H, Nakagaki M, Yao T, Iwasaki H, Ikeda S: Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case. Surg Today; 2005;35(6):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case.
  • Extremely well differentiated primary gastric adenocarcinoma, which accounts for less than 0.2% of all gastric cancers, is associated with a better prognosis than other types of differentiated adenocarcinoma.
  • Among 2070 gastric carcinomas, diagnosed between 1983 and 2002 at Fukuoka University Hospital and Hamanomachi Hospital, there were three cases of primary extremely well differentiated adenocarcinoma.
  • We report the clinicopathological details of one case of primary gastric extremely well differentiated adenocarcinoma.
  • A 57-year-old man was reffered to our hospital for investigation and treatment of a gastric tumor.
  • Macroscopically, the surgical specimen contained a submucosal tumor, and histological examination revealed extremely well differentiated adenocarcinoma.
  • Although this type of carcinoma is very rare, it should be considered in the differential diagnosis of esophageal and gastric mucosal lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Achalasia / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Cardia / pathology. Cell Differentiation. Cholecystectomy. Endoscopy, Digestive System. Esophagus / radiography. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • Genetic Alliance. consumer health - Achalasia.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912298.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


90. van Duin M, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Siersema PD, van Dekken H: High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res; 2007;118(2-4):130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 37 specimens, 21 originated from the esophagus and 16 were derived from the gastric cardia.
  • Quantitative RT-PCR analysis of these seven genes was subsequently performed on a panel of 24 gastroesophageal samples, including 13 cell lines, two xenografts and nine normal stomach controls.
  • Significant overexpression was found for MYC and EXT1 in GEJ adenocarcinoma cell lines and xenografts compared to normal controls.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Esophageal Neoplasms / genetics. Esophagogastric Junction / pathology. Nucleic Acid Conformation. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000363.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


91. Ding GC, Ren JL, Chang FB, Li JL, Yuan L, Song X, Zhou SL, Guo T, Fan ZM, Zeng Y, Wang LD: Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers. World J Gastroenterol; 2010 Dec 14;16(46):5901-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers.
  • AIM: To investigate the relationship between human papillomavirus (HPV) infection and concurrent esophagus and gastric cardia cancer from the same patient (CC) and examine the significance of P16(INK4A) protein expression.
  • RESULTS: Among the CC specimens, HPV16-DNA was found in eight cases of esophageal squamous cell carcinoma (ESCC) and five cases of gastric cardia adenocarcinoma (GCA), respectively (47% vs 29%), and two of both ESCC and GCA.
  • P16(INK4A) may be a screening index in the HPV-associated carcinoma of gastric cardia.
  • [MeSH-major] Cardia / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / genetics. Esophageal Neoplasms / virology. Human papillomavirus 16 / genetics. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):874-8 [10842204.001]
  • [Cites] Dis Esophagus. 2004;17(1):10-26 [15209736.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):929-34 [11375901.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):16-21 [12508343.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1170-3 [12800217.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2003 Nov 10;83(21):1910-4 [14642078.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Diagn Histopathol. 1982 Oct-Dec;5(4):291-6 [6188592.001]
  • [Cites] Ann Epidemiol. 1993 Nov;3(6):577-85 [7921303.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1554-9 [17453003.001]
  • [Cites] Mol Carcinog. 2008 Feb;47(2):100-4 [17918207.001]
  • [Cites] Magy Seb. 2008 Aug;61(4):225-9 [18799406.001]
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Aug;22(4):251-3 [19105334.001]
  • [Cites] J BUON. 2009 Jul-Sep;14(3):495-9 [19810144.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1137-9 [20332262.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Nov;126(11):655-60 [11079730.001]
  • (PMID = 21155014.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC3001984
  •  go-up   go-down


92. Eickhoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff JC, Riemann JF: [Comparison of 3 types of covered self-expanding metal stents for the palliation of malignant dysphagia: results from the prospective Ludwigshafen Esophageal Cancer Register]. Z Gastroenterol; 2005 Oct;43(10):1113-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / complications. Carcinoma, Squamous Cell / complications. Cardia. Deglutition Disorders / therapy. Endoscopy. Esophageal Neoplasms / complications. Registries. Stents. Stomach Neoplasms / complications


93. Akre O, Forssell L, Kaijser M, Norén-Nilsson I, Lagergren J, Nyrén O, Ekbom A: Perinatal risk factors for cancer of the esophagus and gastric cardia: a nested case-control study. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):867-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perinatal risk factors for cancer of the esophagus and gastric cardia: a nested case-control study.
  • In this study, we aimed to test if there is an association between gestational duration and birth weight on the one hand, and risk of esophageal and cardia adenocarcinoma on the other.
  • METHODS: We conducted a nested case-control study of 67 cases of esophageal adenocarcinoma and 93 cases of cardia adenocarcinoma, whereas 50 cases of squamous cell carcinoma were studied for comparison.
  • RESULTS: Long gestational duration was associated with a decreased risk of cardia adenocarcinoma (P(trend) = 0.001) and a nonsignificant decreased risk of esophageal adenocarcinoma (P = 0.07), whereas no such association was found for esophageal squamous cell carcinoma (P = 0.96).
  • Compared with lower maternal age (</=24 years) at giving birth, maternal age of 25 to 29 years were associated with a decreased risk of esophageal adenocarcinoma and squamous cell carcinoma (odds ratio, 0.4; 95% confidence interval, 0.2-0.9 and odds ratio, 0.3; 95% confidence interval, 0.1-0.8, respectively).
  • CONCLUSIONS: Numerical constraints hamper inference, but our results are somewhat consistent with the idea that future risk of esophageal and cardia cancer may in part be determined already perinatally or in infancy and give some limited support to the hypothesis that timing of birth influences risk.
  • [MeSH-major] Birth Weight. Esophageal Neoplasms / epidemiology. Gestational Age. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma. Aged. Carcinoma, Squamous Cell. Cardia. Case-Control Studies. Female. Humans. Infant, Newborn. Logistic Models. Male. Middle Aged. Risk Factors. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702362.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Iizuka H, Kakizaki S, Sohara N, Onozato Y, Ishihara H, Okamura S, Itoh H, Mori M: Stricture after endoscopic submucosal dissection for early gastric cancers and adenomas. Dig Endosc; 2010 Oct;22(4):282-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stricture after endoscopic submucosal dissection for early gastric cancers and adenomas.
  • BACKGROUND AND AIM:  Stricture is a complication that may occur after endoscopic submucosal dissection (ESD) of gastric neoplasms.
  • The goal of the present study was to investigate the incidence, risk factors and management of gastric stricture after ESD.
  • METHODS: The medical records of 308 patients who underwent ESD for gastric neoplasms were reviewed.
  • Three of the six lesions were located in the prepylorus, two cases in the antrum and one in the cardia.
  • However, one patient experienced a gastric perforation and recovered following conservative therapy.
  • CONCLUSION:  Sub-circumferential resection over 75% of the circumference by ESD in the prepylorus, antrum and cardia is a risk factor for the occurrence of stricture.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Gastric Mucosa / surgery. Gastroscopy / methods. Postoperative Complications / therapy. Pyloric Stenosis / therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Digestive Endoscopy © 2010 Japan Gastroenterological Endoscopy Society.
  • (PMID = 21175480.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


95. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D: Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis; 2007 Sep;28(9):1996-2001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
  • This study examined the effect of P53 Arg72Pro variants on transactivation of polymorphic MDM2 promoter (T309G) and their associations with risk of developing gastric cardia adenocarcinoma (GCA) in a Chinese population.
  • [MeSH-major] Amino Acid Substitution. Polymorphism, Genetic. Polymorphism, Single Nucleotide. Proto-Oncogene Proteins c-mdm2 / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638920.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Tumor Suppressor Protein p53; 5Z93L87A1R / Guanine; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; QR26YLT7LT / Thymine
  •  go-up   go-down


96. Lehmann K, Schneider PM: Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:65-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Adenocarcinoma of the distal esophagus, gastric cardia, and upper gastric third are grouped in type I-III by the Siewert classification.
  • [MeSH-major] Adenocarcinoma / genetics. Cardia. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676871.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


97. Bahmanyar S, Ye W: Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer; 2006;54(2):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden.
  • In total 185 patients with esophageal adenocarcinoma, 165 with esophageal squamous-cell carcinoma, 258 with gastric cardia adenocarcinoma, and 815 randomly selected population controls underwent face-to-face interviews.
  • A high score of Western diet was associated with increased risks of gastric cardia adenocarcinoma (high 3rd tertile vs. low 1st quartile, OR = 1.8, 95% CI = 1.1-2.9, P for trend = 0.04) and esophageal adenocarcinoma (high 3rd tertile vs. low 1st tertile, OR = 1.6, 95% CI = 0.9-3.1, P for trend = 0.13), whereas a dietary pattern characterized by high beer and liquor intake (alcohol drinker) significantly increased the risk of squamous-cell carcinoma of the esophagus (3rd tertile vs. low 1st tertile, OR = 3.5, 95% CI = 1.9-6.3, P for trend < 0.0001).
  • Our study confirms the important role of diet in the carcinogenesis of esophageal and cardia cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Food Habits. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Aged. Alcohol Drinking. Cardia. Case-Control Studies. Diet Surveys. Factor Analysis, Statistical. Female. Humans. Male. Meat. Odds Ratio. Risk Assessment. Risk Factors. Sweden / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898861.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA57947-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Trajkov D, Stardelova K, Dimitrova M, Mishevski J, Serafimoski V: Helicobacter pylori and gastric carcinoma. Prilozi; 2007 Dec;28(2):39-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori and gastric carcinoma.
  • The aim of the study was to evaluate the relation of Helicobacter pylori (HP) infection and gastric cancer and a possible relation with a certain histopathological type of gastric cancer and localization within the stomach.
  • A cross-section study was conducted on 60 consecutive patients (45 men and 15 women) with an established histological diagnosis of gastric cancer.
  • The patients were divided into 2 groups (HP positive and HP negative) and additionally, depending on histopathological type, into intestinal, diffuse and cardia cancer, and localization as cardia carcinoma, proximal and distal carcinoma.
  • There were 36 intestinal type of gastric cancer, 34 (94.4%) HP positive (statistically significant), 19 patients with diffuse type, and 8 (42.1%) HP positive.
  • The remaining 5 were carcinoma of cardia and all were HP negative.
  • Thirty-seven (61.7%) were distal carcinomas, up to (76.2%) in the HP positive group, there were 18 (30%) proximal carcinomas and 5 (8.3%) localized on the cardia.
  • This study confirmed the high incidence of HP infection in patients with gastric carcinoma, particularly in those with an intestinal type of cancer.
  • Carcinomas were predominantly localized in the distal part of the stomach, especially in the HP positive group of intestinal type.
  • Carcinomas of cardia were negatively associated with HP infection.


99. Alvarez Herrero L, Pouw RE, van Vilsteren FG, ten Kate FJ, Visser M, van Berge Henegouwen MI, Weusten BL, Bergman JJ: Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy; 2010 Dec;42(12):1030-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens.
  • BACKGROUND: Most risk estimations for lymph node metastasis in adenocarcinoma of the esophagus and cardia (AEC) with invasion into the muscularis mucosae (m3) or submucosa are based on surgical series.
  • [MeSH-major] Adenocarcinoma / secondary. Cardia / pathology. Esophageal Neoplasms / pathology. Mucous Membrane / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20960392.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


100. Gretschel S, Schlag PM: Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach. Recent Results Cancer Res; 2010;182:107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach.
  • The resection of the adenocarcinoma of the esophagogastric junction should be considered to the extent of the lymphatic drainage.
  • As an adenocarcinoma of the esophagogastric junction is located along the borderline between two visceral cavities (mediastinal/abdominal), it can, in principle, metastasize in both cavities.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676875.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down